


SHIVA PHARMACHEM LTD

FINANCIAL STATEMENTS

F.Y.2021-22

A.Y.2022-23



S S B K & Co.

CHARTERED ACCOUNTANTS

A/302, MEGHANSH HABITAT, BEHIND D-MART,
OPP. SWATI APPARTMENT, JIRAJ PARK,
AHMEDABAD- 380051
TEL. (M) 9512922255, 9879397839

SHIVA PHARMACHEM LIMITED
Balance sheet as at 31st March, 2022

Amount in Lakhs

Particulars	Note No	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
I ASSETS				
1 Non-current assets				
(a) Property, plant and equipment	2a	16,733.42	16,155.32	9,606.00
(b) Capital work - in - progress	2b	4,027.70	3,550.02	5,190.88
(c) Intangible assets	3	6.94	7.20	8.15
(d) Right of Use Assets	4	1,093.46	1,145.53	1,197.59
(e) Financial assets				
(i) Investments	5	4,099.37	4,009.29	4,012.79
(ii) Others financial assets	6	525.49	517.53	510.15
(f) Deferred tax assets (net)	7	112.63	125.20	359.00
(g) Other non - current assets	8	306.12	256.03	240.61
Total Non-current assets		26,905.13	25,766.10	21,125.17
2 Current assets				
(a) Inventories	9	10,834.10	7,401.25	6,345.08
(b) Financial assets				
(i) Trade receivables	10	23,412.17	14,239.36	17,964.47
(ii) Cash and cash equivalents	11	464.00	1,558.96	1,203.03
(iii) Bank Balances other than (ii) above	12	36.60	216.97	430.74
(iv) Loans	13	36.48	32.01	36.89
(c) Other current assets	14	8,274.38	5,460.59	8,667.02
Total Current assets		43,057.73	28,909.13	34,647.23
TOTAL ASSETS		69,962.86	54,675.24	55,772.41
II EQUITY AND LIABILITIES				
1 Equity				
a) Equity share capital	15a	708.02	708.02	695.02
b) Other equity	15b	35,628.60	28,190.81	21,488.93
Total Equity		36,336.62	28,898.83	22,183.95
2 Liabilities				
Non-current liabilities				
(a) Financial liabilities				
(i) Borrowings	16a	3,448.89	5,034.20	7,513.24
(ii) Lease Liabilities	16b	10.85	11.07	11.27
(iii) Other financial liabilities	16c	550.00	550.00	550.00
(b) Long Term Provisions	17	807.52	713.21	563.60
(c) Other non-current liabilities	18	365.60	333.67	93.23
Total Non- current liabilities		5,182.86	6,642.15	8,731.33



SHIVA PHARMACHEM LIMITED
Balance sheet as at 31st March, 2022

Amount in Lakhs

Particulars	Note No	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Current liabilities				
(a) Financial liabilities				
(i) Borrowings	19	15,661.53	9,858.23	16,633.05
(ia) Lease Liabilities	20	0.22	0.20	0.19
(ii) Trade payables				
(A) total outstanding dues of micro enterprises and small enterprises; and	21	756.92	999.74	595.99
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	21	7,662.95	4,701.42	3,976.68
(b) Short Term Provisions	22	1,588.99	1,605.96	897.59
(c) Liability for current tax (Net)	23	2,600.00	1,825.69	2,522.42
(d) Other current liabilities	24	172.76	143.02	231.20
Total Current Liabilities		28,443.38	19,134.27	24,857.12
TOTAL EQUITY AND LIABILITIES		69,962.86	54,675.24	55,772.41
SIGNIFICANT ACCOUNTING POLICIES	1			

The accompanying notes are an integral part of these standalone financial statements

As per our Report of even date
For S S B K & Co.
Chartered Accountants
FRN: 134956W

Nitesh Thakkar
CA. Nitesh Thakkar
Partner
Membership No. 158383
Place : Vadodara
Date : 09 NOV 2022



For and on behalf of Board of Directors

Rakesh Agrawal
Rakesh Agrawal
Chairman
DIN:00057955
Place : Vadodara
Date : 09-11-2022

Vishal Agrawal
Vishal Agrawal
Managing Director
DIN:00056800
Place : Vadodara
Date : 09-11-2022

Anil Inani
Anil Inani
Chief Financial Officer
Place : Vadodara
Date : 09-11-2022

Tarang Maru
Tarang Maru
Company Secretary
Place : Vadodara
Date : 09-11-2022

SHIVA PHARMACHEM LIMITED
Statement of Profit & Loss for the year ended 31st March, 2022

Amount in Lakhs

Particulars	Note No.	Year ended 31st March, 2022	Year ended 31st March, 2021
CONTINUING OPERATIONS			
I INCOME			
Revenue from operations	25	70,861.21	52,773.63
Other income	26	1,268.48	1,537.11
Total Income		72,129.69	54,310.74
II EXPENSES			
Cost of materials consumed	27	35,886.69	28,332.00
Purchases of Traded Goods	28	2,140.99	-
Changes in inventories of finished goods and work-in progress	29	(464.71)	(1,296.92)
Employee benefits expense	30	6,548.22	5,546.56
Finance costs	31	573.16	745.20
Depreciation and amortization expense	32	3,732.16	2,260.17
Other expenses	33	13,647.91	9,522.89
Total expenses		62,064.42	45,109.90
III Profit / (loss) before exceptional Items and tax		10,065.27	9,200.83
IV Exceptional Item			
V Profit / (loss) before tax			
VI Tax expense			
Current tax	34	2,600.00	2,300.00
Deferred tax charge/(credit)	34	30.59	126.57
Tax in respect of earlier years		(36.67)	-
VII Profit/(Loss) for the year from continuing operations		7,471.35	6,774.27
VIII Other Comprehensive Income			
(i) Items that will not be reclassified to profit or loss			
Remeasurements of net defined benefit plans		(51.57)	(91.29)
Income tax relating to above items		18.02	31.90
Other comprehensive income for the year		(33.55)	(59.39)
IX Total Comprehensive Income for the year		7,437.80	6,714.87
X Earnings per equity share of INR 10 each (for continuing operation):			
Basic (In Rs.)		105.52	95.68
Diluted (In Rs.)		105.52	95.68
SIGNIFICANT ACCOUNTING POLICIES	1		

The accompanying notes are an integral part of these standalone financial statements

As per our Report of even date

For **S S B K & Co.**
Chartered Accountants
FRN: 134956W

Nitesh Thakkar
CA. Nitesh Thakkar
Partner
Membership No. 158383

Place : Vadodara

Date : 09 NOV 2022



For and on behalf of Board of Directors

Rakesh Agrawal
Rakesh Agrawal
Chairman
DIN:00057955

Place: Vadodara
Date : 09-11-2022

Vishal Agrawal
Vishal Agrawal
Managing Director
DIN:00056800

Place: Vadodara
Date : 09-11-2022

Anil Inani

Anil Inani
Chief Financial Officer

Place: Vadodara
Date : 09-11-2022

Tarang Maru

Tarang Maru
Company Secretary

Place: Vadodara
Date : 09-11-2022

SHIVA PHARMACHEM LIMITED
STATEMENT OF CASH FLOW for the year ended 31st March, 2022

Amount in Lakhs

Particulars	Amount	Year ended 31st March, 2022	Amount	Year ended 31st March, 2021
CASH FLOW FROM OPERATING ACTIVITIES:				
Profit before exceptional Items and tax as per statement of		10,065.27		9,200.83
Adjustments for:				
Depreciation and amortization expenses	3,732.16		2,260.17	
Finance cost	573.16		745.20	
Adjustment for Mat Credit	-		139.13	
Dividend income	0.00		(0.04)	
Interest income	(87.35)		(247.70)	
Remeasurements of net defined benefit plans	(51.57)		(91.29)	
Bad debts / assets written off	-		-	
(Profit)/ loss on sale of fixed assets (net)	(8.38)		(1.62)	
		4,158.01		2,803.84
Operating profit before working capital changes		14,223.28		12,004.68
Adjustments for (Increase)/decrease for:				
Trade & other receivables	(9,172.81)		3,725.11	
Inventories	(3,432.86)		(1,056.16)	
Other Financial Assets	(7.96)		(7.37)	
Other Non Current Assets	(50.09)		(15.42)	
Bank Balance	180.37		213.77	
Short Term Loans	(4.47)		4.88	
Other Current Assets	(2,813.79)		3,206.43	
Lease Liability	(0.22)		(0.20)	
Long Term Provisions	94.31		149.61	
Other Non Current Liability	31.93		240.44	
Short Term Lease Liability	0.02		0.02	
Creditors	2,718.71		1,128.49	
Short Term Provisions	(16.97)		708.37	
Other Current Liabilities	29.74		(88.18)	
Less: Direct taxes paid (net of refunds)	(1,789.02)		(2,996.73)	
		(14,233.10)		5,213.04
Net cash flows (used in)/ generated from operating activities after exceptional items (I)		(9.82)		17,217.72
CASH FLOW FROM INVESTING ACTIVITIES:				
Inflows				
Sale proceeds of property, plant and equipment	21.37		8.40	
Sale proceeds of Investments	-		3.50	
Interest received	87.35		247.70	
Dividend received from others	0.00		0.04	
Outflows				
Purchase of property, plant and equipment/ intangible	(4,748.61)		(7,122.39)	
Purchase of investments (net)	(90.08)		-	
Net cash (used in) / generated from investing activities (II)		(4,729.96)		(6,862.74)



SHIVA PHARMACHEM LIMITED
STATEMENT OF CASH FLOW for the year ended 31st March, 2022

Amount in Lakhs

Particulars	Amount	Year ended 31st March, 2022	Amount	Year ended 31st March, 2021
CASH FLOW FROM FINANCING ACTIVITIES:				
Outflows				
Repayment of long term borrowings	(1,585.31)		(2,479.04)	
Repayment of Short term borrowings	5,803.30		(6,774.82)	
Interest paid	(573.16)		(745.20)	
Net cash (used in) / generated from financing activities (III)		3,644.83		(9,999.05)
NET INCREASE/(DECREASE) IN CASH AND BANK BALANCES (I+II+III)		(1,095)		355.93
Add : Cash and cash equivalence at beginning of the year		1,558.96		1,203.03
Cash and cash equivalence at end of the year		464.00		1,558.96
Cash and Cash equivalent as per above comprises of the		464.00		1,558.96
Cash and Cash Equivalents (Refer Note 11)		464.00		1,558.96
Bank Overdrafts (Refer Note 12)		36.60		216.97
Balances as per statement of Cash Flows		500.60		1,775.93

The accompanying notes are an integral part of these standalone financial statements

Notes:


1 The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) statement of cash flows, whereby profit/ (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature. The cashflows from operating, investing and financing activities of the company are segregated based on the available information.

2 Additions to property, plant, equipment and intangible assets include movements of capital work-in-progress and intangible assets under development respectively during the year.

As per our Report of even date

For S B K & Co.
Chartered Accountants
FRN: 134956W


CA. Nitesh Thakkar



Partner
Membership No 158383

Place : Vadodara

Date : 09-11-2022

For and on behalf of Board of Directors


Rakesh Agrawal

Chairman
DIN:00057955

Place : Vadodara
Date : 09-11-2022


Visha Agrawal

Managing Director
DIN:00056800

Place : Vadodara
Date : 09-11-2022


Anil Inani
Chief Financial Officer

Place : Vadodara

Date : 09-11-2022


Tarang Maru
Company Secretary

Place : Vadodara

Date : 09-11-2022

Note-2a PROPERTY, PLANT & EQUIPMENTS


FY 2020-21

Amount in Lakhs

Sr.No	Particulars	Gross Block			Accumulated Depreciation			Net Block			
		As on 01.04.2020	Additions during the year 20-21	Reduction during the year 20-21	Balance as on 31.03.2021	As on 01.04.2020	Depreciation for FY 20-21	Reduction during the year 20-21	Balance as on 31.03.2020	As on 31.03.2021	As on 31.03.2020
1	Land										
	Owned	36.96	-	-	36.96	-	-	-	-	36.96	36.96
	Leasehold	-	-	-	-	-	-	-	-	-	-
2	Factory Building	4,308.27	633.21	-	4,941.48	1,945.44	247.18	2,192.62	2,748.86	2,362.83	
3	Office Building	251.41	-	-	251.41	87.30	8.06	95.37	156.04	164.10	
4	Office Building-ABS Tower	23.37	-	-	23.37	1.45	1.35	2.80	20.57	21.92	
5	Plant & Machinery	14,683.31	7,595.06	-	22,278.37	10,187.09	1,406.17	11,593.27	10,685.11	4,496.22	
6	Plant Pipe Lines	792.00	-	-	792.00	684.03	33.83	717.86	74.14	107.97	
7	R & D Equipments	200.71	18.22	-	218.93	170.27	7.81	178.08	40.85	30.44	
8	Lab Equipments	59.47	31.49	-	90.96	41.62	14.41	56.03	34.93	17.85	
9	Electrical Installations	658.55	52.55	-	711.11	516.49	41.74	558.23	152.88	142.07	
10	EHS Equipments	67.53	-	-	67.53	54.69	4.02	58.71	8.83	12.84	
11	Furniture	579.16	-	-	579.16	445.71	33.53	479.24	99.92	133.45	
12	Air Conditions	162.07	2.06	-	164.13	135.45	6.46	141.91	22.22	26.62	
13	Computers	127.34	4.61	-	131.95	117.04	4.85	121.89	10.06	10.30	
14	Vehicles	1,145.24	128.21	87.82	1,185.64	730.86	153.78	803.60	382.03	414.38	
15	Office Equipments	154.72	11.68	-	166.40	113.73	15.23	128.96	37.45	40.99	
16	Pollution Control Measures	16.80	162.26	-	179.06	14.36	0.64	14.99	164.07	2.44	
17	ISO Tanks	3,706.14	123.89	-	3,830.03	2,121.55	228.08	2,349.62	1,480.41	1,584.60	
	Total	26,973.06	8,763.25	87.82	35,648.49	17,367.06	2,207.15	19,493.18	16,155.32	9,606.00	

The title deeds of immovable properties which are not held in the name of the Company are as indicated below:

Relevant line item in the Balance sheet	Description of item of property	Gross carrying value	Title deeds held in the name of	Whether title deed holder is a promoter/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company**
Property Plant & Equipments	Land Building	-	-	-	-	-
Investment property -	Land Building	-	-	-	-	-
PPE retired from active use and held for disposal -	Land Building	-	-	-	-	-




Note-2a PROPERTY, PLANT & EQUIPMENTS

FY 2021-22

Sr.No	Particulars	Gross Block				Accumulated Depreciation				Net Block	
		As on 01.04.2021	Additions during the year 21-22	Reduction during the year 21-22	Balance as on 31.03.2022	As on 01.04.2021	Depreciation for FY 21-22	Reduction during the year 21-22	Balance as on 31.03.2022	As on 31.03.2022	As on 31.03.2021
1	Land										
	Owned	36.96	-	-	36.96	-	-	-	-	36.96	36.96
	Leasehold	-	-	-	-	-	-	-	-	-	-
2	Factory Building	4,941.48	595.28	-	5,536.75	2,192.62	294.43	-	2,487.05	3,049.70	2,748.86
3	Office Building	251.41	-	-	251.41	95.37	7.67	-	103.03	148.37	156.04
4	Office Building-ABS Tower	23.37	-	-	23.37	2.80	1.27	-	4.07	19.30	20.57
5	Plant & Machinery	22,278.37	3,117.90	-	25,396.28	11,593.27	2,814.14	-	14,407.40	10,988.87	10,685.11
6	Plant & Pipe Lines	792.00	-	-	792.00	717.86	23.23	-	741.09	50.91	74.14
7	R & D Equipments	218.93	-	-	218.93	178.08	9.98	-	188.06	30.87	40.85
8	Lab Equipments	90.96	122.97	-	213.93	56.03	30.20	-	86.23	127.70	34.93
9	Electrical Installations	711.11	100.24	-	811.34	588.23	45.72	-	603.95	207.39	152.88
10	EHS Equipments	67.53	13.07	-	80.60	58.71	3.79	-	62.50	18.10	8.83
11	Furniture	579.16	86.07	-	665.23	479.24	26.37	-	505.61	159.61	99.92
12	Air Conditions	164.13	30.34	-	194.47	141.91	5.93	-	147.84	46.63	22.22
13	Computers	131.95	5.41	-	137.36	121.89	4.61	-	126.50	10.86	10.06
14	Vehicles	1,185.64	65.52	91.76	1,159.39	803.60	123.41	78.77	848.24	311.15	382.03
15	Office Equipments	166.40	14.17	-	180.58	128.96	15.07	-	144.03	36.55	37.45
16	Pollution Control Measures	179.06	-	-	179.06	14.99	51.04	-	66.03	113.03	164.07
17	ISO Tanks	3,830.03	119.96	-	3,950.00	2,349.62	222.97	-	2,572.60	1,377.40	1,480.41
	Total	35,648.49	4,270.93	91.76	39,827.66	19,493.18	3,679.83	78.77	23,094.24	16,733.42	16,155.32

The title deeds of immovable properties which are not held in the name of the Company are as indicated below:

Relevant line item in the Balance sheet	Description of item of property	Gross carrying value	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative# of promoter*/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company**
Property Plant & Equipments	Land Building	-	-	-	-	-
Investment property -	Land Building	-	-	-	-	-
PPE retired from active use and held for disposal -	Land Building	-	-	-	-	-



Note 2b CAPITAL WORK-IN-PROGRESS

FY 2021-22

Sr.	Particulars	Gross Block				Accumulated Depreciation			Net Block		
		As on 01.04.2021	Addition during the year 21-22	Reduction during the year 21-22	Balance as on 31.03.2022	As on 01.04.2021	Depreciation FY 2021-22	Reduction during the year 21-22	Balance as on 31.03.2022	As on 31.03.2022	As on 31.03.2021
1	CWIP ISO Tanks	46.30	19.05	66.35	0.00	-	-	-	-	46.30	-
2	CWIP Plant & Machinery	3,452.23	3,170.76	4,031.40	2,591.59	-	-	-	2,591.59	3,452.23	-
3	CWIP Factory Building	51.49	1,190.09	21.78	1,219.79	-	-	-	1,219.79	51.49	-
4	CWIP Furniture & Fixtures	-	216.32	-	216.32	-	-	-	216.32	-	-
	Total	3,550.02	4,596.22	4,118.53	4,027.70	-	-	-	4,027.70	3,550.02	-

As at 31st March, 2022

Particulars	Amount in Lakhs			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
Projects in progress	3,288.70	431.33	307.65	-
Projects temporarily suspended	-	-	-	-
Total	3,288.70	431.33	307.65	4,027.70

As at 31st March, 2021

Particulars	Amount in Lakhs		
	Less than 1 year	1-2 years	More than 3 years
Projects in progress	2,649.76	900.27	-
Projects temporarily suspended	-	-	-
Total	2,649.76	900.27	3,550.02

For FY 2020-21


Sr.	Particulars	Gross Block				Accumulated Depreciation			Net Block		
		As on 01.04.2020	Additions during the year 20-21	Reduction during the year 20-21	Balance as on 31.03.2021	As on 01.04.2020	Depreciation FY 2020-21	Reduction during the year 20-21	Balance as on 31.03.2021	As on 31.03.2021	As on 31.03.2020
1	CWIP ISO Tank	-	140.79	94.49	46.30	-	-	-	46.30	-	-
2	CWIP Plant & Machinery	5,183.21	6,669.90	8,400.88	3,452.23	-	-	-	3,452.23	5,183.21	-
3	CWIP Factory Building	7.67	175.89	132.07	51.49	-	-	-	51.49	7.67	-
	Total	5,190.88	6,986.58	8,627.44	3,550.02	-	-	-	3,550.02	5,190.88	-

As at 31st March, 2021

Particulars	Amount in Lakhs			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
Projects in progress	2,649.76	900.27	-	-
Projects temporarily suspended	-	-	-	-
Total	2,649.76	900.27	-	3,550.02

As at 1st April, 2020

Particulars	Amount in Lakhs		
	Less than 1 year	1-2 years	More than 3 years
Projects in progress	4,821.56	369.32	-
Projects temporarily suspended	-	-	-
Total	4,821.56	369.32	5,190.88



Note 3 - INTANGIBLE ASSETS


Amount in Lakhs

Particulars	Amount
Gross carrying amount	
Deemed Cost as at 1st April, 2020	160.85
Additions during the year	-
Disposals during the year	-
Balance as at 31st March, 2021	160.85
Additions during the year	-
Disposals during the year	-
Balance as at 31st March, 2022	160.85
Accumulated amortisation	
Balance as at 1st April, 2020	152.70
Additions during the year	0.95
Disposals during the year	-
Balance as at 31st March, 2021	153.65
Additions during the year	0.26
Disposals during the year	-
Balance as at 31st March, 2022	153.91
Net carrying amount	
Balance as at 1st April, 2020	8.15
Balance as at 31st March, 2021	7.20
Balance as at 31st March, 2022	6.94

Note 4 - RIGHT OF USE ASSET

Amount in Lakhs

Particulars	Amount
Gross Carrying amount	
Balance as at 1st April, 2020	1,316.47
Additions during the year	-
Disposals during the year	-
Balance as at 31st March, 2021	1,316.47
Additions during the year	-
Disposals during the year	-
Balance as at 31st March, 2022	1,316.47
Accumulated Depreciation	
Balance as at 1st April, 2020	118.87
Additions during the year	52.07
Disposals during the year	-
Balance as at 31st March, 2021	170.94
Additions during the year	52.07
Disposals during the year	-
Balance as at 31st March, 2022	223.01
Net carrying amount	
Balance as at 31st March, 2020	1,197.59
Balance as at 31st March, 2021	1,145.53
Balance as at 31st March, 2022	1,093.46



Note 5 - FINANCIAL ASSETS - INVESTMENTS

Amount in Lakhs

Particulars	As at 31st March, 2022		As at 31st March, 2021		As at 1st April, 2020	
	No. of Units	Amount	No. of Units	Amount	No. of Units	Amount
A. Investment in Subsidiaries, Associates & Joint Ventures						
Unquoted At Fair value through Other Comprehensive Income						
i. Equity instruments at cost						
SES Engineering Private Limited (50,000 Equity shares of Rs. 10 each fully paid up)	50,000	5.00	50,000	5.00	50,000	5.00
Shiva AG (1,00,000 Equity Shares of CHF 1/- each fully paid up)	1,00,000	66.58	1,00,000	66.58	1,00,000	66.58
Investment in KisChemicals Manufacturing & Mercantile Limited Liability Company (55,20,66,666 shares - 70% Quota)	-	2,422.86	-	2,422.86	-	2,422.86
Sidhan Speciality Chemicals Private Limited (10,000 Equity Shares of Rs. 10/- each fully paid up)	10,000	1.00	10,000	1.00	-	-
Investment in Sisley Properties LLP	-	1,171.48	-	1,171.48	-	1,171.48
ii. Preference Shares						
SES Engineering Private Limited (42,95,300 Preference Shares of Rs. 10 each at Amortised Cost:*) (Equity Component of Compound financial instruments) *Balance amount in Note 6	42,95,300	337.38	42,95,300	337.38	42,95,300	337.38
Total (A)		4,004.29		4,004.29		4,003.29
B. Other Equity Instruments						
Unquoted At Fair value through Other Comprehensive Income						
Enviro Infrastructure Co. Limited (50,000 Equity shares of Rs. 10 each fully paid)	50,000	5.00	50,000	5.00	50,000	5.00
Total (B)		5.00		5.00		5.00
C. Preference Shares						
Unquoted At Fair value through Other Comprehensive Income						
Enviro Infrastructure Co. Limited (45,000 Preference shares of Rs. 10 each)	-	-	-	-	45,000	4.50
Onesto Labs Pvt Ltd (15,000 Preference Shares of Rs. 10 each fully paid at FVTPL)	15,000	90.08	-	-	-	-
Total (C)	15,000	90.08	-	-	45,000	4.50
Non-current Investments total (A+B+C)		4,099.37		4,009.29		4,012.79
(a) Aggregate book value of quoted investment	-	-	-	-	-	-
(b) Aggregate market value of quoted investment	-	-	-	-	-	-
(c) Aggregate amount of unquoted investment	-	4,099.37	-	4,009.29	-	4,012.79
(d) Aggergate amount of impairment in value of investment.	-	-	-	-	-	-



Note 6 - OTHER NON-CURRENT FINANCIAL ASSETS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Financial Assets - Preference Shares	99.53	92.15	92.15
Add : Interest Income - Preference Shares	7.96	7.37	-
Total	107.49	99.53	92.15
Call option Agreement-Zull Patel	209.00	209.00	209.00
Call option Agreement-Gaurav Astik	209.00	209.00	209.00
Total	525.49	517.53	510.15

Note 7 - DEFERRED TAX ASSET (NET)

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Deferred Tax Asset	112.63	125.20	359.00
Total	112.63	125.20	359.00

Component of Deferred Tax Liabilities/(Asset)

Amount in Lakhs

Particulars	Opening balance	Charge / Credit To		Closing balance
		Statement of Profit & Loss	Other Comprehensive Income	
As on 01-04-2020				
Deferred tax liabilities / (asset) in relation to:				
Property, Plant and Equipments	517.74	(324.91)	-	192.84
ROU asset	(418.49)	18.20	-	(400.29)
Provision for Gratuity and Leave Enchashment	255.74	31.58	31.90	319.22
Lease Liability	4.00	(0.07)	-	3.94
Provision for expected credit loss	-	9.50	-	9.50
As on 31st March 2021	359.00	(265.70)	31.90	125.20
As on 01-04-2021				
Deferred tax liabilities / (asset) in relation to:				
Property, Plant and Equipments	192.84	(79.14)	-	113.70
ROU asset	(400.29)	18.20	-	(382.10)
Provision for Gratuity and Leave Enchashment	319.22	30.43	18.02	367.67
Lease Liability	3.94	(0.07)	-	3.87
Provision for expected credit loss	9.50	-	-	9.50
As on 31st March 2022	125.20	(30.59)	18.02	112.63



Note 8 - OTHER NON-CURRENT ASSETS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Other Investments			
Paintings & Art Works	13.40	13.40	13.40
Deposits Given	136.94	86.85	71.43
Capital Advances			
Advances to Vendors for Capital Goods	155.78	155.78	155.78
Total	306.12	256.03	240.61

Note 9 - INVENTORIES

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Raw Materials	5,905.30	2,907.86	3,468.24
Work-in Progress	3,048.47	2,378.01	1,364.74
Finished goods (Other than those acquired for trading)	404.64	610.39	326.75
Packing Material	111.69	96.98	69.83
Stores and Spares	704.85	551.39	453.38
Stocks In Transit	659.15	856.61	662.14
Total	10,834.10	7,401.25	6,345.08

(a) Inventories are measured at lower of cost (Net of Input GST credit availed if any) or Net Realisable Value.

Note 10 - CURRENT FINANCIAL ASSETS - TRADE RECEIVABLES

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Secured, Considered Good			
Unsecured, Considered Good*	23,439.35	14,266.54	17,964.47
Significant increase in Credit Risk	-	-	-
Credit Impaired	-	-	-
Less: Provision for Expected Credit Loss Allowances	(27.18)	(27.18)	-
Total	23,412.17	14,239.36	17,964.47
* Includes receivable from related parties, in which director of the Company is a director or member			
Shiva Pharmachem AG	5,369.15	4,477.89	3,314.07
Shiva Pharmachem International Inc	3,107.16	1,399.57	4,278.37
	8,476.31	5,877.46	7,592.44



10.1 Trade Receivables ageing

As at 31 March 2022


Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 Years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables — considered good	23,020.77	340.75	6.83	24.19	-	23,392.54
(ii) Undisputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables — credit impaired	-	-	-	-	-	-
(iii) Undisputed Trade Receivables — credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables — considered good	-	19.63	-	-	-	19.63
(v) Disputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(v) Disputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables — credit impaired	-	-	-	-	-	-

As at 31 March 2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 Years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables — considered good	14,085.68	143.00	10.68	-	-	14,239.36
(ii) Undisputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables — credit impaired	-	-	-	-	-	-
(iii) Undisputed Trade Receivables — credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables — considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(v) Disputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables — credit impaired	-	-	-	-	-	-

As at 01 April 2020

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 Years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables — considered good	17,902.25	60.61	-	1.61	-	17,964.47
(ii) Undisputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables — credit impaired	-	-	-	-	-	-
(iii) Undisputed Trade Receivables — credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables — considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(v) Disputed Trade Receivables — which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables — credit impaired	-	-	-	-	-	-



Note 11 - CASH AND CASH EQUIVALENTS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Cash on hand	-	-	0.12
Balances with Schedule Banks - In current accounts	464.00	1,558.96	1,202.92
Total	464.00	1,558.96	1,203.03

Note 12 - BANK BALANCES OTHER THAN CASH AND CASH EQUIVALENTS


Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Bank balances other than cash and cash equivalents (i) In other deposit Accounts Margin Money Deposits - Original maturity more than 3 months but less than / equal to 12 months	36.60	216.97	430.74
Total	36.60	216.97	430.74

Note 13: CURRENT FINANCIAL ASSETS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
(i) Loans to Related Parties Unsecured - considered good	-	4.20	2.36
(ii) Loans & Advances to employees Unsecured - considered good	-	-	-
Loans given	32.91	18.20	27.16
Advances given	3.56	9.61	7.37
Total	36.48	32.01	36.89



Note 14: OTHER CURRENT ASSETS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Prepaid expenses	132.04	112.27	97.38
Insurance Claim Receivable	87.26	87.26	87.26
Advances for Capital Goods	401.92	-	-
Receivable from Related party (Refer Note No.5 of additional Information)	1,732.71	1,853.81	3,356.06
Advances to Suppliers			
To Related Parties	1,531.00	-	-
To Others	310.75	539.56	1,271.01
Total	1,841.75	539.56	1,271.01
Balances with Government Authorities			
Advance Income Tax & TDS	3,144.01	2,361.13	3,374.28
Custom Authorities	74.47	5.12	3.28
IGST Rebate	7.22	7.22	49.04
Export - Duty Draw Back Receivable	18.05	-	-
IGST Refund - DTA Unit	800.79	435.99	369.14
IGST Refund - SEZ Unit	-	17.58	24.58
Customs Duty & IGST Refund - SEZ Unit	34.15	-	-
VAT Refund	-	40.65	35.00
Total	4,078.70	2,867.70	3,855.32
Total	8,274.38	5,460.59	8,667.02



Note 15a - EQUITY SHARE CAPITAL

Particulars	As at 31st March, 2022		As at 31st March, 2021		As at 1st April, 2020	
	Number of shares	Amount In Lakhs	Number of shares	Amount In Lakhs	Number of shares	Amount In Lakhs
Authorised Share Capital						
Equity Shares of Rs. 10/- each	1,35,00,000	1,350.00	80,00,000	800.00	70,00,000	700.00
Preference Shares of Rs. 100 each (8.5% CCPS)	6,00,000	600.00	-	-	-	-
Note : Upon the scheme of arrangement coming into effect, the authorised share capital of the VRFPL (transferor Company) amounting to Rs. 5,50,00,000 (55,00,000 equity share of Rs. 10 each) will get consolidated with that of the SPL (Transferee Company). The Authorised Capital increased from the date of NCLT Order i.e. 26-09-2022.						
Issued, subscribed and paid up						
Equity Shares of Rs. 10/- each	70,80,200	708.02	70,80,200	708.02	69,50,200	695.02
Total	70,80,200	708.02	70,80,200	708.02	69,50,200	695.02


Notes:

a) Reconciliation of number of shares

Particulars	As at 31st March, 2022		As at 31st March, 2021		As at 1st April, 2020	
	Number of shares	Amount In Lakhs	Number of shares	Amount In Lakhs	Number of shares	Amount In Lakhs
Equity Shares :						
Balance as at the beginning of the year	70,80,200	708.02	70,80,200	708.02	69,50,200	695.02
Shares issued during the year	70,80,200	708.02	70,80,200	708.02	69,50,200	695.02
Balance as at the end of the year						

b) Rights, preferences and restrictions attached to shares

Equity shares: The Company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.




c) Details of equity shares held by shareholders holding more than 5% of the aggregate shares in the Company

Particulars	As at 31st March, 2022		As at 31st March, 2021		As at 1st April, 2020	
	No. of shares	% of holding	No. of shares	% of holding	No. of shares	% of holding
Tash Investment Pvt Ltd	-	0%	-	0%	58,70,000	84.46%
Rakesh Agrawal	18,00,180	25.42%	18,00,180	25.42%	-	0.00%
Uma R Agrawal	18,00,180	25.42%	18,00,180	25.42%	-	0.00%
Vishal R Agrawal	15,20,780	21.48%	15,20,780	21.48%	5,39,900	7.77%
Rahul R Agrawal	16,60,700	23.46%	16,60,700	23.46%	5,39,900	7.77%

d) Disclosure of Shareholding of Promoters:

Shares held by promoters at the end of the year (31.03.2022)

Promoter Name	No. of Shares**	% of total shares	% Change during the year
Rakesh Agrawal	18,00,100	25.42%	-
Vishal R Agrawal	15,20,780	21.48%	-
Rahul R Agrawal	16,60,700	23.46%	-



Note 15b - OTHER EQUITY

Particulars	Reserve & Surplus				Other Equity		Other Comprehensive Income		Total
	Share Capital	Capital Redemption Reserve	General Reserves	Retained Earnings	Share Capital Pending Allotment	Capital Redemption Reserve	Remeasurement of defined benefit liability		
	Pending Allotment	Reserve		Earnings					
Balance as at 1st April, 2020	13.00	400.00	-	21,003.61	-	400.00	72.32	21,488.93	
Transfer to Retained Earnings / General Reserves	-	(400.00)	400.00	-	-	(400.00)	-	-	
Total Comprehensive Income for the year	-	-	-	6,774.27	-	-	(59.39)	6,714.87	
Converted into Share Capital	(13.00)	(0.00)	-	-	-	(0.00)	-	(13.00)	
Balance as at 31st March, 2021	-	(0.00)	400.00	27,777.88	-	(0.00)	12.93	28,190.81	
Total Comprehensive Income for the year	-	-	-	7,471.35	-	-	(33.55)	7,437.80	
Balance as at 31st March, 2022	-	(0.00)	400.00	35,249.23	-	(0.00)	(20.62)	35,628.60	


The accompanying notes are an integral part of these standalone financial statements

As per our Report of even date

For S B K & Co.

Chartered Accountants

Firm Registration Number: 134956W



(Signature)
CA. Nitesh Thakkar
 Partner
 Membership No. 158383
 Place : Vadodara
 Date : 09 NOV 2022

For and on behalf of Board of Directors

(Signature)
Vishal Agrawal
 Managing Director
 DIN:00056800
 Place : Vadodara
 Date: 09-11-2022

(Signature)
Anil Inani
 Chief Financial Officer
 Place : Vadodara
 Date: 09-11-2022

(Signature)
Tarang Maru
 Company Secretary
 Place : Vadodara
 Date: 09-11-2022

Note 16a - NON-CURRENT BORROWINGS

Amount in Lakhs

Particulars	As at	As at	As at
	31st March, 2022	31st March, 2021	1st April, 2020
Secured Loan			
Term Loans from banks			
HDFC Bank Ltd	3,429.75	4,758.13	5,347.50
Less: Current Maturity of Long-term Debts	1,502.86	1,307.50	632.50
	1,926.89	3,450.63	4,715.00
Deferred payment Liabilities			
Yes Bank-Car Loan	-	7.57	24.55
Less: Current Maturity of Long-term Debts [Refer Note-A Below]	-	-	-
		7.57	24.55
IIFI Wealth Finance	-	-	1,388.27
Axis Bank Car Loan	-	-	65.96
Less: Current Maturity of Long-term Debts	-	-	-
Secured - Total (A)	1,926.89	3,458.20	6,193.78
Unsecured Loans from Directors / Shareholders			
Loans from Directors / Shareholders	1,522.00	1,576.00	1,319.46
Unsecured - Total (B)	1,522.00	1,576.00	1,319.46
Total (A+B)	3,448.89	5,034.20	7,513.24

16a.1 Secured loans referred above to the extent of :

* Rs. 3429.75 Lakhs term loan (Rs.1926.89 Lakhs-Non current and Rs 1502.85 Lakhs-Current) is Secured by way of Pari Passu charge over entire movable and immovable fixed assets of the company , both present and future located at company's Luna plant. And entire plant and machinery and land and building located at company's Dahej Plant)

(It is further secured by way of personal guarantee of Mr.Rakesh Agrawal and Mr.Vishal Agrawal)

16a.2 Maturity Profile of term loan are set out below

Amount in Lakhs

Particulars	Non-Current		Current
	5 Years above	1 – 5 Years	1 Year
Secured from Banks	-	1,926.89	1,503

Note 16b - NON CURRENT LEASE LIABILITIES


Amount in Lakhs

Particulars	As at	As at	As at
	31st March, 2022	31st March, 2021	1st April, 2020
Lease Liability (Dahej Land)	11.07	11.27	11.46
Less : Current Maturities of Lease Liability	(0.22)	(0.20)	(0.19)
Total	10.85	11.07	11.27

Note 16c - OTHER NON CURRENT FINANCIAL LIABILITIES

Amount in Lakhs

Particulars	As at	As at	As at
	31st March, 2022	31st March, 2021	1st April, 2020
Preference Share Capital Pending Allotment	550.00	550.00	550.00
Total	550.00	550.00	550.00



Note 17 - LONG TERM PROVISIONS


Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Provision for Retirement Benefits	1,052.16	913.51	731.85
Less: Current Maturity of Long-term Debts	(244.64)	(200.30)	(168.25)
Total	807.52	713.21	563.60

Note 18 - OTHER NON CURRENT LIABILITIES

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Trade/Security Deposits received	42.49	139.70	34.87
Interest Payable on Non Current borrowing	323.11	193.97	58.36
Total	365.60	333.67	93.23



Note 19 - CURRENT BORROWINGS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
(a) Loans from banks:			
<u>Secured:</u>			
Bill Discounting	-	-	2,676.53
PCFC with Banks	14,158.67	8,399.92	12,735.15
(Secured by way of Pari Passu charge over entire current assets all movable fixed assets and over immovable property of the company situated at Luna Ta. Padra Dist. Baroda)			
(The above facility is further secured by personal guarantee of the directors)			
<u>Unsecured loan</u>			
-From Related Party	-	5.10	-
(b) Current maturities of Long term borrowings:			
Standard Chartered Bank-ECB	-	-	496.31
HDFC Bank-Term Loans	1,502.86	1,307.50	632.50
Yes Bank - Car Loan	-	16.99	15.46
Union Bank Of india - Car Loan	-	62.77	-
Axis Bank - Car Loan	-	65.96	77.10
Total	15,661.53	9,858.23	16,633.05

Note 20 - CURRENT LEASE LIABILITY


Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Lease liability for Dahej SEZ Land	0.22	0.20	0.19
Total	0.22	0.20	0.19

Note 21 - TRADE PAYABLES

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
(A) Total Outstanding dues of micro enterprises and small	756.92	999.74	595.99
(B) Total Outstanding dues of creditors other than micro enterprises and small enterprises	7,662.95	4,701.42	3,976.68
Total	8,419.87	5,701.16	4,572.67



Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
i. Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	756.92	999.74	595.99
ii. Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end on above amount	1.28	1.87	-
iii. Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-	-
iv. Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-	-
v. Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-	-
vi. Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-	-
vii. Further interest remaining due and payable for earlier years	-	-	-

The above has been determined to the extent such parties could be identified on the basis of information available with the company regarding the status of suppliers under MSME.

16.1 Trade Payables ageing

As at 31st March, 2022

Amount in Lakhs

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	504.35	240.81	11.13	0.63	-	756.92
(ii) Others	4,088.76	3,541.88	17.98	14.33	-	7,662.95
(iii) Disputed dues — MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

As at 31st March, 2021

Amount in Lakhs

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	635.65	352.31	10.54	1.24	-	999.74
(ii) Others	2,381.65	2,285.53	23.18	3.47	7.58	4,701.42
(iii) Disputed dues — MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

As at 1st April, 2020

Amount in Lakhs

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	247.41	341.27	7.32	-	-	595.99
(ii) Others	1,947.54	2,002.85	17.88	6.10	2.31	3,976.68
(iii) Disputed dues — MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-



Note 22 - SHORT TERM PROVISIONS

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Provision for employee benefits			
Provision for retirement benefits	244.64	200.30	168.25
Provision others			
Provisions for Expenses	685.20	549.05	67.20
Provisions for Stock in Transit	659.15	856.61	662.14
Total	1,588.99	1,605.96	897.59

Note-23 LIABILITY FOR CURRENT TAX

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
Provision for Income tax	2,600.00	1,825.69	2,522.42
Total	2,600.00	1,825.69	2,522.42

Note 24 - OTHER CURRENT LIABILITIES

Amount in Lakhs

Particulars	As at 31st March, 2022	As at 31st March, 2021	As at 1st April, 2020
1. Statutory Payable			
TDS Payable	54.09	24.57	58.46
TCS Payable	0.26	1.35	0.04
IGST Payable	38.75	13.63	87.33
ESI Payable	0.75	1.05	1.25
Providend Fund Payable	53.24	44.33	37.25
2. Advance from Customers	25.68	58.10	46.86
Total	172.76	143.02	231.20



Note 25 - REVENUE FROM OPERATIONS

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Sale of Products		
(i) Manufactured goods (Net)	68,636.92	52,773.63
(ii) Traded Sales	2,224.29	-
Total	70,861.21	52,773.63

Sale of Manufactured goods comprises of :


Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Domestic Sales	23,708.09	16,628.85
Export Sales	39,997.17	32,582.12
Deemed Export Sales	4,931.66	3,562.66
Total	68,636.92	52,773.63

Note 26 - OTHER INCOME

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Gain on foreign currency transaction and translation (Net)	621.05	587.04
Interest income comprises:		
Other Interest	87.35	247.70
Interest Income - Preference Shares (Financial Assets)	7.96	7.37
	95.32	255.08
Dividend Income	0.00	0.04
Profit on Sale of Assets	8.38	1.62
Export Promotion Benefits	483.46	691.11
Insurance claim received - Employees	6.37	-
Insurance claim received - Finished Goods	39.64	-
Rent Income	-	2.00
Miscellaneous Income	14.25	0.22
Total	1,268.48	1,537.11



Note 27 - COST OF MATERIALS CONSUMED

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Opening Stock	2,907.86	3,468.24
Jobwork Charges	234.54	393.31
Purchases	38,649.59	27,378.32
Total	41,792.00	31,239.86
Less : Closing Stock	5,905.30	2,907.86
Total	35,886.69	28,332.00

Note 28 - PURCHASES OF STOCK-IN-TRADE

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Purchase of traded goods	2,140.99	-
Total	2,140.99	-

Note 29 - CHANGES IN INVENTORIES OF FINISHED GOODS AND WORK-IN-PROGRESS

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2022
Closing Inventories		
Finished Goods	404.64	610.39
Work in Process	3,048.47	2,378.01
Total	3,453.11	2,988.41
Opening inventories		
Finished Goods	610.39	326.75
Work in Process	2,378.01	1,364.74
Total	2,988.41	1,691.49
Total	464.71	1,296.92

Note 30 - EMPLOYEE BENEFITS EXPENSE


Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Salaries and wages, Bonus and other allowances	5,330.62	4,432.75
Contribution to provident funds, Family Pension and ESIC	328.02	278.49
Gratuity & Leave Encashment Expense	163.88	147.85
Workmen and Staff welfare expenses	725.70	687.46
Total	6,548.22	5,546.56

Note 31 - FINANCE COSTS

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Interest and other borrowing cost on Borrowings from banks	492.75	643.75
Bank Charges	79.50	100.53
Interest on lease liability	0.90	0.92
Total	573.16	745.20



Note 32 - DEPRECIATION AND AMORTIZATION EXPENSE

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Depreciation on Property, Plant and Equipment	3,679.83	2,207.15
Amortization on Intangible assets	0.26	0.95
Amortization on Right of Use Assets	52.07	52.07
Total	3,732.16	2,260.17

Note 33 - OTHER EXPENSES

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Computer Expenses	16.08	12.17
Donation	39.62	42.51
Duties & Taxes	43.46	45.54
EHS Expenses	1,846.98	920.26
Electricity Expense	18.33	12.33
Expected Credit Loss allowance	-	27.18
Insurance Premium	225.86	152.12
Insurance Medical Claim	-	1.27
Legal & Professional Expenses	196.64	247.52
CSR Expenses	300.10	70.01
Sitting Fees	10.50	13.00
Packing Material	602.82	481.70
Statutory Audit Fees (Refer Note 33.1 below)	4.49	3.65
Internal Audit Fees	5.50	7.50
Interest on Statutory Payments	94.04	79.19
Postage & Telephone	37.15	29.77
Power & Fuel	3,944.14	2,343.51
Printing & Stationery	11.02	10.58
Laboratory Expenses	81.60	79.96
Lease Rent - ISO Tanks	411.73	408.67
Rent Others	83.00	12.39
Repairs & Maintenance - Building	85.45	97.11
Repairs & Maintenance - Plant & Machinery	701.77	544.78
Repairs & Maintenance - ISO Tanks	137.46	93.16
Repairs & Maintenance - Others	59.12	61.07
Sales Commission	57.30	29.81
Security Expenses	123.20	110.42
Selling & Distribution Expenses	2,926.50	2,277.07
Stores & Spares	1,070.33	829.42
Travelling & Conveyance	179.44	129.95
Vehicle Expenses	17.43	15.98
Miscellaneous Expenses	316.85	333.27
Total	13,647.91	9,522.89

33.1 Payment to Auditors comprises of:

Amount in Lakhs

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
<u>Auditors' remuneration and expenses:</u>		
For Audit Fees	4.49	3.65
For Other services *	2.95	1.85
Total	7.44	5.50

* Other services of Rs.2.95 Lakhs (P.Y 1.85 Lakhs) have been included in Legal & Professional Expenses.



Note 34 - INCOME TAXES EXPENSE

Particulars	Amount in Lakhs	
	Year ended 31st March, 2022	Year ended 31st March, 2021
Tax expense recognized in the Statement of Profit and Loss		
i. Recognised in Statement of Profit and Loss		
Current tax	2,600.00	2,300.00
Deferred tax		
Deferred tax charge/(credit)	(30.59)	265.70
MAT Credit (taken)/utilised	-	(139.13)
Total deferred income tax expense/(benefit)	(30.59)	126.57
Total income tax expense	2,569.41	2,426.57


A reconciliation of the income tax expenses to the amount computed by applying the statutory income tax rate to the profit before income taxes is summarized below:

Particulars	Amount in Lakhs	
	Year ended 31st March, 2022	Year ended 31st March, 2021
Profit before tax	10,065.27	9,200.83
Income Tax Expenses Calculated at 34.944%	3,522.24	3,219.74
Effect of Income that is exempt from Tax	(708.61)	(811.81)
Effect of expenses that are not deductible in determining taxable profit	1,483.49	957.00
Effect of consession (allowance)	(1,398.25)	(1,118.19)
Effect of Brought Forwarded Losses due Scheme of Merger (ref. note below)	(276.86)	-
Adjustments recognised in current year in relation to the current tax of prior years	(36.67)	-
Others	8.58	179.84
Income tax expense recognised in profit or loss	2,593.92	2,426.57

Note: pursuant to the scheme of arrangement of merger of VR Finechem Pvt Ltd("VRFL") with Shiva Pharmachem Limited("SPL"), brought forwarded losses of the Transferor Company("VRFL") which are available to claimed as per the provisions of Income Tax Act, 1961 has been set off for calculation of Tax Expenses of the Transferee Company("SPL"). The brought forwarded losses amounting to INR. 791.18 Lakhs pertaining to Assessment Years 2018-19 to 2021-22 were set-off in compliance with the provisions of the act.

Note 35 - EARNING PER SHARE

Particulars	Amount in Lakhs	
	Year ended 31st March, 2022	Year ended 31st March, 2021
Basic and Diluted earnings per share (Rs)		
From continuing operations (Rs.)	105.52	95.68
From discontinued operations (Rs.)	-	-
Total Basic and Diluted earnings per share (Rs.)	105.52	95.68
Footnotes:		
The earnings and weighted average numbers of equity shares used in the calculation of basic and diluted earnings per share are as follows.		
(a) Earnings used in the calculation of basic and diluted earnings per share:		
Profit for the year from continuing operations	7,471.35	6,774.27
Profit for the year from discontinued operations	-	-
(b) Weighted average number of equity shares used in the calculation of basic and diluted earnings per share:		
Weighted average number of equity shares used in the calculation of basic and diluted earnings per share from continuing operations and from discontinued operations	70.80	70.80



Note 36 - FINANCIAL RATIO ANALYSIS :

Ratios	Numerator	Denominator	2021-22	2020-21	% Variance
Current Ratio	Current Assets	Current Liabilities	1.51	1.51	0.20
Debt-Equity Ratio	Total Debt	Shareholder's Equity	0.93	0.89	3.75
Return on Equity ratio	Net Profits after taxes - Preference Dividend	Average Shareholder's Equity	23%	27%	(13.64)
Inventory Turnover ratio	Cost of goods sold	Average Inventory	4.12	3.93	4.74
Net Capital Turnover Ratio	Net sales = Total sales - sales return	Working capital = Current assets - Current liabilities	4.85	5.40	(10.19)
Net Profit ratio	Net Profit	Net sales = Total sales - sales return	11%	13%	(17.86)
Return on Capital Employed	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability	19%	22%	(15.30)



Note 37 - Related Party Transactions

1. Related Party Disclosure as per Ind AS – 24:

As per the Indian Accounting Standard-24 on "Related Party Disclosures", list of related parties identified of the Company are as follows:

(A) Parent Company:

The Company is having no Parent company as at 31.03.2022

(B) Subsidiary/Joint Ventures/Associate/Others

Company / Entity	Type
Shiva Pharmachem AG	Wholly Owned Subsidiary Company
Shiva Pharmachem INC.	Wholly Owned Subsidiary Company
SES Engineering Pvt. Ltd.	Wholly Owned Subsidiary Company
Sidhan Specialty Chemicals Pvt Ltd	Wholly Owned Subsidiary Company
KisChemicals Manufacturing & Mercantile Limited Liability Company	Subsidiary Company
Sisley Properties LLP	LLP in which Capital Contribution is made
Geetganga Investment Pvt Ltd	Company in which Key Managerial Personnel have control
Shiva Performance Materials Pvt Ltd	Company in which Key Managerial Personnel have control
Shiva Foundation	Entity over which Key Managerial Personnel have significant influence.
Uttarayan Foundation & Museum for Art	Entity over which Key Managerial Personnel have significant influence.
Uttarayan Art Foundation	Entity over which Key Managerial Personnel have significant influence


List of related parties having transactions during the year:

Key Managerial Personnel includes Directors as well as Chief Financial Officer and Company Secretary as identified under Section 2 of Companies Act, 2013.

Name of Related Parties	Nature of Relationship	Nature of Transactions	2021-22 Amount (Rs. In Lakhs)	2020-21 Amount (Rs. In Lakhs)
Mr. Rakesh Agrawal – Chairman	Key Managerial Personnel	Salary	180.40	180.40
		Conveyance	1.04	-
		Interest	1.26	16.27
Mr. Vishal R Agrawal – Managing Director	Key Managerial Personnel	Remuneration	441.22	331.30
		Conveyance	8.47	6.78
		Interest	-	-
Mr. Rahul R Agrawal – Jt. Managing Director	Key Managerial Personnel	Remuneration	99.13	-
		Conveyance	-	-
		Interest	-	-



Mr. Jagmohan Zalani – Director	Key Managerial Personnel	Salary	67.67	64.72
		Conveyance	2.39	2.13
		Conveyance	-	-
Mr. Tarang Maru – Company Secretary	Key Managerial Personnel	Salary	8.81	6.60
*Chirag Patel – Chief Financial Officer	Key Managerial Personnel	Salary	0.19	-
		Conveyance	0.02	-
Tash Investment Pvt Ltd	Holding Co.	Rent	-	4
		Interest	-	-
Geetganga Properties Pvt Ltd	Co. in which Key Managerial Personnel have control	Rent	4.80	1.60
Shiva Pharmachem AG	Wholly Owned Subsidiary Co.	Sales	15,468.33	13,692.31
		Advance purchases	1,531	-
Shiva Pharmachem INC.	Wholly Owned Subsidiary	Sales	8,241.15	5,308.02
Geetganga Investment Pvt Ltd	Co. in which Key Managerial Personnel have control	Rent	65	-
		Interest	144.38	120.93
Shiva Foundation	Entity over which Key Managerial Personnel have significant influence.	Donation	8	6
Uttarayan Foundation & Museum for Art	Entity over which Key Managerial Personnel have significant influence.	Donation	2	5
Uttarayan Art Foundation	Entity over which Key Managerial Personnel have significant influence	Donation / CSR	83	54
SES Engineering Pvt. Ltd.	Wholly Owned Subsidiary	Services	-	5.50
Shiva Performance	Co. in which Key Managerial	Sales	2,118.27	-
		Purchases	14.51	-



Materials Pvt Ltd	Personnel have control
-------------------	------------------------

*Note: Mr. Chirag Patel has been appointed as Chief Financial Officer of the Company as on 30th March 2022.

Loans From Related Parties:

Name of Related Party	Nature of Relationship	Balance as on 01-04-2021	Amount Accepted	Interest for the Year	(Amount In Lakhs)	
					Amount Repaid	Balance as on 31.03.2022
Rakesh S Agrawal - Chairman	Key Managerial Personnel	61	-	1.26	62.26	-
Geetganga Investment Pvt Ltd	Co. in which Key Managerial Personnel have control	1,515	7	144.38	-	1,666.38


Director Sitting Fees:

Name of Related Parties	Nature of Relationship	Nature of Transactions	2021-22 Amount (Rs In Lakhs)
Milin K Mehta – Director	Key Managerial Personnel	Sitting Fees	2.80
Purshottamdas Dhumal – Director	Key Managerial Personnel	Sitting Fees	2.90
Sivaraman Narayanswami – Director	Key Managerial Personnel	Sitting Fees	4.30
Uma Agrawal – Director	Key Managerial Personnel	Sitting Fees	0.50

Disclosure on Loans/Advance to Directors/ KMP/ Related parties:

The Company has not granted any Loans repayable on demands or any loans specifying any terms or period of repayment.

Type of Borrower	Amount of loan or advance in the nature of loan Outstanding	Percentage to the total Loans and Advances in the nature of loans
Promoters	NIL	NIL
Directors	NIL	NIL
KMPs	NIL	NIL
Related Parties	NIL	NIL
Total	NIL	NIL



Note 38 - FAIR VALUE MEASUREMENT

A. Accounting classification and fair values

As at March 31, 2022

Amount in Lakhs

Particulars	FVTPL	FVTOCI	Amortised Cost	Total	Fair Value			Total
					Level 1 - Quoted price in active markets	Level 2 - Significant observable inputs	Level 3 - Significant unobservable inputs	
Investments*	-	-	4,099.37	4,099	-	-	-	-
Trade receivables	-	-	23,412.17	23,412	-	-	-	-
Cash and cash equivalents	-	-	464.00	464	-	-	-	-
Other bank balance	-	-	-	-	-	-	-	-
Loans	-	-	-	-	-	-	-	-
Other financial assets	-	-	-	-	-	-	-	-
Total Financial assets	-	-	27,976	27,976	-	-	-	-
Borrowings (incl. current maturities)	-	-	-	-	-	-	-	-
Other Non current Liabilities	-	-	-	-	-	-	-	-
Trade payables	-	-	8,419.87	8,420	-	-	-	-
Other financial liabilities	-	-	-	-	-	-	-	-
Total Financial liabilities	-	-	8,420	8,420	-	-	-	-

Amount in Lakhs

As at March 31, 2021

Particulars	FVTPL	FVTOCI	Amortised Cost	Total	Fair Value			Total
					Level 1 - Quoted price in active markets	Level 2 - Significant observable inputs	Level 3 - Significant unobservable inputs	
Investments*	-	-	4,009	4,009	-	-	-	-
Trade receivables	-	-	14,239.36	14,239	-	-	-	-
Cash and cash equivalents	-	-	1,558.96	1,559	-	-	-	-
Other bank balance	-	-	-	-	-	-	-	-
Loans	-	-	-	-	-	-	-	-
Other financial assets	-	-	-	-	-	-	-	-
Total Financial assets	-	-	19,808	19,808	-	-	-	-
Borrowings (incl. current maturities)	-	-	-	-	-	-	-	-
Other Non current Liabilities	-	-	-	-	-	-	-	-
Trade payables	-	-	5,701	5,701	-	-	-	-
Other financial liabilities	-	-	-	-	-	-	-	-
Total Financial liabilities	-	-	5,701	5,701	-	-	-	-

*Investment in note 6 includes investments in subsidiaries and joint ventures which are carried at cost and hence are not required to be disclosed as per Ind AS 107 "Financial Instruments Disclosures". Hence, the same have been excluded from the above table.


B. Measurement of fair values

The below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follow:

Level 1: Quoted prices in active markets for identical assets and liabilities.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).



NOTE 38 - Financial instruments – Fair values and risk management

The Company's principal financial liabilities comprises of trade and other payables. The Company's financial assets include trade and other receivables, and cash & cash equivalents that it derives directly from its operations.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's senior management oversees the management of these risks. The Company's senior management is supported by the Board of Directors that advises on financial risks and the appropriate financial risk governance framework for the Company. This provides assurance to the Company's senior management that the Company's financial risk activities are governed by appropriate policies and procedure and that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives. The Board of Directors reviews and agrees policies for managing each risk, which are summarised as below:

(i) **Credit risk**

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its obligations. The Company is exposed to credit risk for trade receivables and other financial assets.

Other financial assets

Other financial assets includes loan to employees, security deposits, investments, cash and cash equivalents, other bank balance, advances to employees etc.

- Cash and cash equivalents and Bank deposits are placed with banks having good reputation and past track record with adequate credit rating.
- The Company has given security deposit to various government authorities. Being government authorities, the Company does not have exposure to any credit risk.

Trade and other receivables

The exposure to credit risk on accounts receivables and amounts due from related parties is monitored on an ongoing basis by the management and these are considered recoverable by the company's management. Accounts receivables were outstanding from few customers and hence the Company has concentration of accounts receivables and consequent risk to that extent.

In view of the management based on the company's past history as well as forward looking estimates at the end of each reporting period, receivables are good and fully recoverable.

The following year end trade receivables, loans and other financial assets balances, though overdue, are expected to be realised in the normal course of business and hence, are not considered impaired as at March 31, 2021 and March 31, 2020 :

Particulars	Amount in Lakhs	
	31st March 2022	31st March 2021
Neither impaired nor past due		
Past due but not impaired		
0-3 Months	23,020.77	14,085.68
3-6 Months	-	-
6-12 Months	360.39	143.00
more than 365 days	31.02	10.68
Total	23,412.17	14,239.37

Movements in expected credit loss allowance

Particulars	Amount in Lakhs	
	31st March 2022	31st March 2021
Balance at the beginning of the year	27.18	-
Movements in allowance	-	27.18
Balance at the end of the year	27.18	27.18

The maximum exposure to credit risk for trade and other receivables by geographic region was as follows:



Financial instruments – Fair values and risk management (Cont'd...)

(ii) Liquidity risk

The Company requires funds both for short-term operational needs as well as for long-term investment programmes mainly in growth. Management monitors forecasts of the Company's liquidity position and cash and cash equivalent on the basis of expected cash flows.

Financing arrangement

The Company had access to the following undrawn borrowing facilities at the end of the reporting period:


Particulars	Amount in Lakhs	
	31st March 2022	31st March 2021
Fixed Rate		
Expiring within one year (bank overdraft and other facilities)	-	-
Expiring beyond one year (bank overdraft and other facilities)	-	-
	-	-

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.

As at 31st March 2022	Carrying amount	Total	Contractual maturities	
			Less than 12 months	More than 12 months
Non-derivative financial liabilities				
Borrowings (incl. current maturities)	19,110.42	19,110.42	1,502.86	17,607.56
Trade payables	8,419.87	8,419.87	8,419.87	-
Other current financial liabilities	0.22	0.22	0.22	-
Total	27,530.51	27,530.51	9,922.95	17,607.56

As at 31st March 2021	Carrying amount	Total	Contractual maturities	
			Less than 12 months	More than 12 months
Non-derivative financial liabilities				
Borrowings (incl. current maturities)	14,892.43	14,892.43	9,865.80	5,026.63
Trade payables	5,701.16	5,701.16	5,701.16	-
Other current financial liabilities	0.20	0.20	0.20	-
Total	20,593.80	20,593.80	15,567.16	5,026.63



Financial instruments – Fair values and risk management (Cont'd...)

(iii) **Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of interest rate risk, currency risk and other price risk, such as equity price risk and commodity risk. Financial instruments affected by market risk include loans and borrowings and deposits.

(a) **Currency risk**

Currency risk faced by the company is minimal as there are minimal foreign currency transactions. Most of the monetary assets and liabilities are denominated in United States Dollar (USD).

(b) **Interest rate risk**

Interest rate risk is the risk of variability in profit due to change in interest rates on interest bearing assets and interest bearing

Exposure to interest rate risk

The interest rate profile of the Company's interest - bearing financial instrument as reported to management is as follows:

Particulars	Amount in Lakhs	
	31st March 2022	31st March 2021
Fixed-rate instruments		
Financial assets	-	-
Financial liabilities*	-	-
Variable-rate instruments		
Financial assets	-	-
Financial liabilities	-	-
Non-interest bearing instruments		
Financial assets**	28,574.10	20,574.11
Financial liabilities	-	-

Sensitivity analysis

Particulars	Impact on profit before tax	
	31st March 2022	31st March 2021
Interest rate		
- increase by 50 basis points	-	-
- decrease by 50 basis points	-	-

(c) **Investment Price Risk**

The Company is exposed to the risk of its investment not being recovered.




NOTE - 39 CAPITAL MANAGEMENT

The Company determines the amount of capital required on the basis of the annual business plan coupled with long term and short term strategic investments and expansion plans. The funding needs are met through equity, cash generated from operations, long terms and short term bank borrowings.

The Company monitors capital using a ratio of 'adjusted net debt' to 'adjusted equity'. For this purpose, adjusted net debt is defined as total liabilities, comprising interest-bearing loans and borrowings, less cash and cash equivalents. Adjusted equity comprises all components of equity.

The Company's adjusted net debt to equity ratio is as follows.

Particulars	Amount in Lakhs	
	31st March 2022	31st March 2021
Borrowings	19,110.42	14,892.43
Less : Current Investment	-	-
Less : Cash and bank balances	464.00	1,558.96
Adjusted net debt	18,646.42	13,333.47
Borrowings	19,110.42	14,892.43
Total equity	36,336.62	28,898.83
Adjusted net debt to adjusted equity ratio	0.51	0.46
Debt equity ratio	0.53	0.52



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

Corporate information:

Shiva Pharmachem Limited (the company) having CIN U24231GJ1999PLC035615 is a Public Unlisted Company incorporated in India. The Registered office of the Company is located at 12th Floor, SHIVA, Sarabhai Complex, Dr. Vikram Sarabhai Marg, Vadiwadi, Vadodara 390023, Gujarat (India).

The company is engaged in the business of manufacturing and is a Global supplier of Acid, Alkyl Chlorides, and advanced intermediates.

Significant Accounting Policies:

1. Basis of preparation and presentation

Compliance with Ind AS:

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended).

For all periods up to and including the year ended March 31, 2021, the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements for the year ended March 31, 2022 are the first the Company has prepared in accordance with Ind AS.

The date of transition to Ind AS is April 1, 2020. Refer Note 1A for the details of first-time adoption exemptions availed by the Company. In accordance with Ind AS 101 First-time Adoption of Indian Accounting Standard, the Company has presented a reconciliation from the presentation of financial statements under Accounting Standards notified under the Companies (Accounting Standards) Rules, 2014 ("Previous GAAP") to Ind AS of Shareholders' equity as at March 31, 2021 and April 1, 2020 and of the comprehensive net income for the year ended March 31, 2021 and April 1, 2020. Refer **Note 1A** for information on how the Company adopted Ind AS.

Historical Cost Convention:


The financial statements have been prepared on a historical cost basis, except for

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments) and
- ii. Defined Benefits Plan – Plan Assets are measured at Fair Value.

These Ind AS financial statements are presented in Indian Rupees (INR) which is also the Company's functional currency.

2. Use of estimates

The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Application of accounting policies that require critical accounting estimates involving complex and subjective judgements and the use of assumptions in these financial statements have been disclosed in notes below. Accounting estimates could change from period to period. Actual results could



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

differ from these estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and if material, then effects are disclosed in the notes to the financial statements.

3. Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle; or
- Held primarily for the purpose of trading; or
- Expected to be realized within twelve months after the reporting period; or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle; or
- It is held primarily for the purpose of trading; or
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

4. Property, Plant and Equipment (PPE):

Recognition and Measurement:

All items of PPE are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation, and accumulated impairment losses, if any. Cost of an item of PPE comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the assets. Other Indirect Expenses incurred relating to project, net of income earned during the project development stage prior to its intended use, are considered as pre-operative expenses and disclosed under Capital Work-in-Progress.

Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

If significant parts of an item of PPE have different useful lives, then they are accounted for as separate items (major components) of PPE. The Company has carried out the technical review for identification of significant components with different useful life with that of useful life of the original assets to which it belongs. However, based on technical analysis, it has been noticed



Shiva Pharmachem Limited**Notes to Ind AS Financial Statements for the year ended on 31st March 2022:**

that the useful life of the significant components are more or less remain the same with that of the original assets to which it belongs so no separate useful life are assigned to significant components. All the Significant Components are depreciated based on the same useful life with that of original assets to which it belongs.

Depreciation:

Depreciation on items of Property, Plant and Equipment is provided to the extent of depreciable amount on the Written down Value (WDV) Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013 except in respect of following categories of assets, in whose case the life of the assets has been assessed as under based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, and maintenance support, etc.


Sr. No.	Class of Assets	Useful Life (Years)
1	Continuous Plant & Machinery	12 Years

Freehold land is not depreciated. Leasehold land (ROU) is amortised over the period of lease. Useful Life considered for calculation of depreciation for various class of assets are as under

Sr.No.	Class of Assets	Useful Life (Years)
1	Factory Building	30
2	Office Building	60
3	Plant & Machinery	12
4	Plant Pipelines	8
5	R&D Equipments	10
6	Lab Equipments	8
7	Electrical Installation	8
8	EHS	8
9	Furniture	10
10	Air Conditioner	10
11	Computers	3
12	Vehicles	8
13	Office Equipment	5
14	Pollution Control Measures	8
15	ISO Tanks	20

The residual values, useful lives and methods of depreciation of Property, Plant and Equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de-recognition of a Property, Plant and Equipment are measured as the difference between the net disposal proceeds and the carrying amount of



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

the asset and are recognised in the Statement of Profit and Loss when the asset is derecognised.

Revision in Useful Life of Plant & Machinery:

During the Financial Year 2021-2022, the Company has carried out assessment of all Plant & Machinery and based on its assessment the Company's Management has decided to increase the Useful Life of all the Plant & Machinery from 8 Years to 12 Years prospectively with effect from 01st April 2021.

Due to Change in useful life of Plant & Machinery, the Depreciation during the year has been reduced by the following amount:

Particulars	Useful Life	Depreciation Rs. (In Lakhs)
Plant & Machinery	8 Years (Original)	3704.25
Plant & Machinery	12 Years (Revised)	2814.14
Depreciation reduced by		890.11

Transition to Ind AS :

For Transition to Ind AS, the Company has elected to continue with the carrying value of all of its PPE recognised as at 01 April, 2020 measured as per the previous Indian GAAP and use that carrying value as the deemed cost of the PPE except for Lease Hold Land.

5. Capital work in Progress

Projects under which tangible assets are not yet ready for their intended use and other capital work-in-progress are carried at cost, comprising direct cost, related incidental expenses and attributable borrowing costs.

CWIP incurred during the period of implementation of a project, till it is commissioned, is accounted as Capital work-in-progress and after commissioning the same is transferred / allocated to the respective item of PPE.

6. Intangible Assets

Recognition and measurement

Intangible assets are recognised when it is probable that the future economic benefits that are attributable to the assets will flow to the Company and the cost of the asset can be measured reliably. Intangible assets are initially measured at cost. Such intangible assets are subsequently measured at cost less accumulated amortisation and any accumulated impairment losses.

Transition to Ind AS


For transition to Ind AS, the Company has elected to continue with the carrying value of all of its intangible assets recognised as at 01 April, 2020 measured as per the previous Indian GAAP and use that carrying value as the deemed cost of the intangible assets.

Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognised in Statement of Profit and Loss as incurred.

Amortisation

Intangible assets are amortised over the estimated period of benefit.



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

A summary of the policies applied to the Company's intangible assets is as follows:

Intangible Assets	Method of Amortisation	Useful Life Years
Computer Software	WDV	6 Years

7. Leases:

The Group evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgement.

The Group uses judgement in assessing whether a contract (or part of contract) include a lease, the lease term (including anticipated renewals), the applicable discount rate, variable lease payments whether are in-substance fixed. The judgement involves assessment of whether the asset included in the contract is a fully or partly identified asset based on the facts and circumstances, whether the contract include a lease and non-lease component and if so, separation thereof for the purpose of recognition and measurement, determination of lease term basis, inter alia the non-cancellable period of lease and whether the lessee intends to opt for continuing with the use of the asset upon the expiry thereof, and whether the lease payments are fixed are variable or a combination of both.

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

For arrangements entered into prior to April 01, 2020, the Company has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

Short-term leases and leases of low-value assets


The Company applies the short-term lease recognition exemption to its short-term leases of ISO Tanks (i.e. those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). Further the above lease also qualifies for low-value assets recognition exemption as they are considered to be low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

The Company has entered into Lease Agreement with M/s. Shruti Marine Services to take on lease ISO tanks for 12 Months (i.e. Rent Agreement will be renewed on Year on Year basis). Due to Lease Agreement validity for 12 Months falling under the criteria of "Short Term Lease" the ROU assets and liability not created as per IND AS 116.

Also the Company has entered into Lease Agreement with M/s. Eurotainer to take on lease ISO tanks for 36 Months but the Rent Agreement will be renewed on Year on Year basis. Due to Lease Agreement validity for 12 Months falling under the criteria of "Short Term Lease" the ROU assets and liability not created as per IND AS 116.

8. Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

The Company determines the classification of its financial assets and liabilities at initial recognition. The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows.

i. Financial Assets

A. Initial Recognition and Measurement

All Financial Assets are initially recognised at fair value. Transaction costs that are directly attributable to the acquisition or issue of Financial Assets, which are not at Fair Value Through Profit or Loss, are adjusted to the fair value on initial recognition. Purchase and sale of Financial Assets are recognised using trade date accounting.

B. Subsequent Measurement

a) Financial Assets measured at Amortised Cost (AC)

A Financial Asset is measured at Amortised Cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the Financial Asset give rise to cash flows on specified dates that represent solely payments of principal and interest on the principal amount outstanding.

b) Financial Assets measured at Fair Value Through Other Comprehensive Income (FVTOCI)

A Financial Asset is measured at FVTOCI if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling Financial Assets and the contractual terms of the Financial Asset give rise on specified dates to cash flows that represents solely payments of principal and interest on the principal amount outstanding. The Company has made an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in Other Comprehensive Income based on its business model.

On de-recognition of such Financial assets, cumulative gain or loss previously recognised in Other Comprehensive Income is not reclassified from the equity to statement of Profit and Loss.

c) Financial Assets measured at Fair Value through Profit or Loss (FVTPL)

A Financial Asset which is not classified in any of the above categories are measured at FVTPL.

Financial assets are reclassified subsequent to their recognition, if the Company changes its business model for managing those financial assets. Changes in business model are made and applied prospectively from the reclassification date which is the first day of immediately next reporting period following the changes in business model in accordance with principles laid down under Ind AS 109 – Financial Instruments.

C. Investment in Subsidiaries, Associates and Joint Ventures

The Company has accounted for its investments in Subsidiaries, associates and joint venture at cost less impairment loss (if any). The investments in preference shares with the right of surplus assets which are in nature of equity in accordance with Ind AS 32 are treated as separate category of investment and measured at FVTOCI.

D. Other Equity Investments

All other equity investments are measured at fair value, with value changes recognised in Statement of Profit and Loss, except for those equity investments for which the Company has elected to present the value changes in 'Other Comprehensive Income'. However, dividend



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

on such equity investments are recognised in Statement of Profit and loss when the Company's right to receive payment is established.

As on the date of transition to IND AS, the Company has taken carrying amount of investment of M/s. Enviro infrastructure Co Limited as its Fair Value in absence of availability of Fair Value per share.

E. Impairment of Financial Assets

In accordance with Ind AS 109, the Company uses 'Expected Credit Loss'(ECL) model, for evaluating impairment of Financial Assets other than those measured at Fair Value Through Profit and Loss (FVTPL). Expected Credit Losses are measured through a loss allowance at an amount equal to:

- The 12-months expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date); or
- Full lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument).

For Trade Receivables the Company applies 'simplified approach' which requires expected lifetime losses to be recognised from initial recognition of the receivables. The Company uses historical default rates to determine impairment loss on the portfolio of trade receivables. At every reporting date these historical default rates are reviewed and changes in the forward looking estimates are analysed.

For other assets, the Company uses 12 month ECL to provide for impairment loss where there is no significant increase in credit risk. If there is significant increase in credit risk full lifetime ECL is used.

ii. Financial Liabilities

A. Initial Recognition and Measurement

All Financial Liabilities are recognised at fair value and in case of borrowings, net of directly attributable cost. Fees of recurring nature are directly recognised in the Statement of Profit and Loss as finance cost.

B. Subsequent Measurement


Financial Liabilities are carried at amortised cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

iii. De-recognition of Financial Instruments

The Company derecognises a Financial Asset when the contractual rights to the cash flows from the Financial Asset expire or it transfers the Financial Asset and the transfer qualifies for de-recognition under Ind AS 109. A Financial liability (or a part of a Financial liability) is derecognised from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

iv. Offsetting

Financial Assets and Financial Liabilities are offset and the net amount is presented in the balance sheet when, and only when, the Company has a legally enforceable right to set off the amount and it intends, either to settle them on a net basis or to realise the asset and settle the liability simultaneously.



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

9. Fair Value Measurement

The Company measures financial instruments, such as, investments, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability,
- In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their best economic interest. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, which gives highest priority to quoted prices in active markets and the lowest priority to unobservable inputs.

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2 — Valuation techniques for inputs other than quoted prices included within Level 1 that are observable for the asset or Liability either directly or indirectly.

Level 3 — Valuation techniques for inputs that are unobservable for the asset or liability.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

10. Impairment of non-financial assets


The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

The Company's corporate assets (e.g., central office building for providing support to various CGUs) do not generate independent cash inflows. To determine impairment of a corporate asset, recoverable amount is determined for the CGUs to which the corporate asset belongs.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

and loss except for properties previously revalued with the revaluation surplus taken to Other Comprehensive Income (OCI). For such properties, the impairment is recognised in OCI up to the amount of any previous revaluation surplus. An impairment loss in respect of assets for which impairment loss has been recognised in prior periods, the Company reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognized.

11. Foreign Currencies Transactions and Translation

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date. Exchange differences arising on settlement or translation of monetary items are recognised in Statement of Profit and Loss except to the extent of exchange differences which are regarded as an adjustment to interest costs on foreign currency borrowings that are directly attributable to the acquisition or construction of qualifying assets which are capitalised as cost of assets.

Non-monetary items that are measured in terms of historical cost in a foreign currency are recorded using the exchange rates at the date of the transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e. translation differences on items whose fair value gain or loss is recognised in Other Comprehensive Income or Statement of Profit and Loss are also recognised in Other Comprehensive Income or Statement of Profit and Loss, respectively).


In case of an asset, expense or income where a non-monetary advance is paid/received, the date of transaction is the date on which the advance was initially recognised. If there were multiple payments or receipts in advance, multiple dates of transactions are determined for each payment or receipt of advance consideration.

12. Cash and Cash Equivalents

The Company considers all highly liquid financial instruments, which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents. Cash and cash equivalents consist of balances with banks which are unrestricted for withdrawal and usage.

13. Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

A contingent liability is

- (a) a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or
- (b) a present obligation that arises from past events but is not recognised because
 - (i) it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or
 - (ii) the amount of the obligation cannot be measured with sufficient reliability.

Disclosure of contingent liability is made when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources embodying economic benefits will be required to settle or a reliable estimate of amount cannot be made.

A contingent asset is a possible asset that arises from the past events and whose existence will be confirmed only by the occurrence or non- occurrence of one or more of uncertain future events not wholly within the control of the entity. Contingent assets are disclosed in the Financial Statements by way of notes to accounts when an inflow of economic benefits is probable.

14. Revenue Recognition (Revenue from Contracts with Customers):

The Company derives Revenue primarily from sale of manufactured products being "Chemicals". Revenue from contracts with customers is recognised when the control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

(a) Sale of Goods:

Revenue from sale of goods is recognised at the point of time when control of the goods is transferred to the customer, generally on dispatch/delivery of the goods except in case of Export Sales, which are recognised on the basis of Bill of Lading on satisfaction of performance obligation and transfer of control.

Sale of goods is recognised net of sales returns and trade discounts. Sales excludes amounts of indirect taxes on sales.

(b) Dividend and interest income:

Dividend income from investments is recognised when the Company's right to receive the payment has been established, which is generally when shareholders approve the dividend.

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on time basis, by reference to the principal outstanding and at the effective interest rate applicable.

For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR), which is the rate that exactly discounts the estimated future cash payments or



Shiva Pharmachem Limited**Notes to Ind AS Financial Statements for the year ended on 31st March 2022:**

receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. Interest income is included in other income in the statement of profit and loss.

(c) Insurance Claims:

Claims receivable on account of insurance are accounted for to the extent no significant uncertainty exists for the measurement and realisation of the amount.

Insurance Claims, other than claim filed against fire accident, have been booked on receipt basis.

15. Inventories:

Inventories have been valued on the following basis:

Nature of Inventories	Basis of Inventories Valuation
Raw Material Stock	Inventories of Raw Materials are valued at the lower of cost and net realisable value. Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on Weighted Average basis. Cost of raw material excludes all taxes and duties.
Semi-Finished (WIP) Goods Stock	Semi-Finished (WIP) Goods Stocks are valued at cost plus appropriate overheads directly attributable to manufacturing activity.
Finished Goods Stock	Inventories of Finished Goods are valued at the lower of cost and net realisable value. Cost represents material, labour and manufacturing expenses and other incidental costs to bring the inventory in present location and condition.
Packing Material Stock	Packing Material stocks are valued at cost.
Stores & Spares Stock	Stores & Spares stocks are valued at cost.
Stock in Transit	Stock in transit stocks is valued at material cost.

As management is of the view that the goods are mainly intended to be exported and hence GST has not been added in valuation of Finished Goods.

Further Imported Goods received in Factory during April 2022 has been included in Inventories as goods in transit as on Balance Sheet date.



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

16. Employee Benefits Expense

Short-Term Employee Benefits

The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees are recognised as an expense during the period when the employees render the services.

Post-Employment Benefits

Defined Contribution Plans

The Company's contribution paid / payable during the year to Provident Fund and other welfare funds are considered as defined contribution plans. The contribution paid/payable under those plans are recognised as an expense, in the Statement of Profit and Loss during the period in which the employee renders the services.

If the contribution payable to the scheme for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the scheme is recognised as a liability. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognised as an asset to the extent that the pre-payment will lead to a reduction in future payment or a cash refund.

Defined Benefit Plans

The Company pays gratuity to the employees who have completed five years of service with the Company at the time of resignation superannuation. The gratuity is paid @15 days' basic salary for every completed year of service as per the Payment of Gratuity Act, 1972.

The liability in respect of gratuity and other post-employment benefits is calculated using the Projected Unit Credit Method and spread over the period during which the benefit is expected to be derived from employees' services.

Actuarial gains and losses are recognised immediately in the Statement of Profit and Loss and Other Comprehensive Income.

17. Tax Expenses

The tax expenses for the period comprises of current tax and deferred income tax. Tax is recognised in Statement of Profit and Loss, except to the extent that it relates to items recognised in the Other Comprehensive Income. In which case, the tax is also recognised in Other Comprehensive Income.

i. Current Tax

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the Income Tax authorities, based on tax rates and laws that are enacted at the Balance sheet date.

ii. Deferred Tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the Financial Statements and the corresponding tax bases used in the computation of taxable profit.

Deferred tax assets are recognised to the extent it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax losses can be utilised. Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The carrying amount of Deferred tax liabilities and assets are reviewed at the end of each reporting period.



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

18. Borrowing Costs:

Borrowing costs includes interest & exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur.

19. Investments in Subsidiaries:

A subsidiary is an entity that is controlled by the Company.

The Company accounts for the investments in equity shares of subsidiaries at Cost in accordance with Ind AS 27 – Separate Financial Statements.

20. Earnings per share

Basic earnings per share is computed by dividing the profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period. Diluted earnings per share is computed by dividing the profit after tax by the weighted average number of equity shares considered for deriving the basic earnings per share and the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.

21. Segment Reporting:

The operating segment has been identified and reported taking into account its internal financial reporting, performance evaluation and organizational structure of its operations. Operating segment is reported in the manner evaluated by Board, considered as Chief Operating Decision Maker under Ind AS 108 “Operating Segment”.

The Company has only one segment of activity, namely “Manufacturing of Chemicals”, in accordance with the definition of “Segment” covered under Indian Accounting Standards (Ind AS) 108 on Operating Segments. Presently, the Company’s operations are predominantly confined in India.

The performance of the Company is discussed in this Report.

22. Event occurred after the Balance Sheet Date

The Company evaluates events and transactions that occur subsequent to the balance sheet date but prior to the approval of the financial statements to determine the necessity for recognition and/or reporting of any of these events and transactions in the financial statements. There were no material subsequent events to be recognized or reported except the following:


- (a) The Scheme of Arrangement of VR Finechem Private Limited into Shiva Pharmachem Limited has been approved by the Honourable NATIONAL COMPANY LAW TRIBUNAL, AHMEDABAD COURT NO. II vide its Order No. CP(CAA) 12/AHM/2022 IN CA(CAA) 70/230-232/AHM/2021 Dated - 26th September 2022. **The said Arrangement has been effective from 01st April 2021. The Scheme has accordingly been given effect in this financial statement with effect from 01st April 2021.**



Shiva Pharmachem Limited

Notes to Ind AS Financial Statements for the year ended on 31st March 2022:

- (b) Pursuant to the Scheme of Arrangement One fully paid-up Compulsorily Convertible Preference Share of INR 100 (Indian Rupees Hundred) of SPL, the Transferee Company, shall be issued for every Ten equity shares of INR 10 (Indian Rupees Ten) each of VR Finechem Pvt Limited, the Transferor Company, held by such shareholder whose name is recorded in the register of members of the Transferor Company, on the record date (i.e.26-09-2022).
- (c) Pursuant to the scheme of arrangement become effective the authorised share capital of the VRFPL (transferor Company) amounting to Rs. 550 Lakhs (55,00,000 equity share of Rs. 10 each) will get consolidated with that of the SPL (Transferee Company). Accordingly, the total authorised capital increased from the date of NCLT Order i.e., 26-09-2022.



Shiva Pharmachem Limited
Additional information pursuant to Schedule III :

1. Disclosure of Changes in Estimates

- i. Effect of Change in estimate on the current period
- ii. If applicable and practicable, effect of change in estimate on the future periods
- iii. If applicable and impracticable, the fact that it is impracticable to estimate the effect on future periods.

2. Corporate Social Responsibility (CSR):

- CSR amount required to be spent as per section 135 of the Companies Act, 2013 read with schedule VII thereof by the company during the year is Rs. 214.91 Lakhs (Previous year Rs. 154.29 Lakhs)
- Actual expenditure related to CSR spent during the year is Rs. 45.10 Lakhs (Previous year Rs. 70.01 Lakhs)
- Shortfall in spending related to CSR activities during the year is Rs. 169.81 Lakhs (Previous year Rs. 84.28 Lakhs)
- Unspent amount pertains to year as on 31st March 2022 is Rs. 169.81 Lakhs. Company has opened separate CSR Account and transferred Rs. 170.00 Lakhs for its Art ongoing project, which is going to be utilized in next three years.

Particulars	(Amount in Lakhs)	
	2021-22	2020-21
Health (including COVID -19)	22.00	16.75
Education	6.61	3.87
Art, Culture and Heritage	10.94	47.00
Rural Development	5.55	2.39
	45.10	70.01

- The unspent amount of previous year relating to an ongoing project has been spent in current financial year. The amount is contributed to Uttarayan Art foundation Rs. 83.00 Lakhs and Rs. 2 Lakhs to Uttarayan foundation for Museums and Arts which is related parties of SPL.

3. Contingent Liability

- (a) As on 31st March 2022, the company has a contingent liability of Rs. 1977.21 Lakhs constituted by Letter of Credits and Bank Guarantees. Further with respect to Unpaid Disputed Statutory Dues, the contingent liability Outstanding as on 31st March 2022 is as follows:

Bank	Letter of Credit/ Bank Guarantee	Amount (In Rs. Lakhs)
HDFC Bank	Letter of Credit	206.29
CITI Bank	Letter of Credit	1654.54
IDBI Bank	Bank Guarantee	116.37
	TOTAL	1977.20



Shiva Pharmachem Limited
Additional information pursuant to Schedule III :

(b) Contingent Liabilities in respect of LC/BG utilised by SES Engineering Pvt Ltd for which Shiva Pharmachem Limited has given the security:

Bank	Letter of Credit/ Bank Guarantee	Amount (In Rs. Lakhs)
IDBI Bank	Bank Guarantee	59.01
TOTAL		59.01

(c) Corporate Guarantees given by Shiva Pharmachem Limited during FY 2021-2022:

Sr. No.	Nature of Transactions	Date of Transactions	Name of Person	Amount (In Rs. Lakhs)	Purpose
1	Corporate Guarantee	12/05/2021	MKB Bank Public Limited 1056, Budapest, Vaci utca 38, Hungary	1960.00	For providing guarantee to MKB Bank Public Limited for HUF credit agreement for investment entered into by Kis chemicals kft Shiva Pharmachem Ltd. Is guarantor / obligor for Kis chemicals kft.
2	Corporate Guarantee	12/05/2021	K & H Bank ZRT H-1056, Budapest, Lechner Odon Fasor 9, Hungary	900.47	
3	Corporate Guarantee	12/05/2021	Ministry of Foreign Affairs and Trade of Hungary 1027- Budapest, Hungary	12,556.55	Ministry of Foreign Affairs and Trade of Hungary (obligee) and Kischchemicals kft (beneficiary) concluded agreement for supporting investment project. Shiva Pharmachem Ltd. (Surety) guarantees in favour of obligee the repayment of amount of subsidy provided to beneficiary.
Total Rs.				15,417.02	



Shiva Pharmachem Limited

Additional information pursuant to Schedule III :

(d) The Company has no disputed tax demands, in respect of excise duty, service tax custom duty, value added tax and sales tax as they have opted for "Sabka Vishwas Scheme" and "Vera Samadhan Yojna" except the following liabilities in respect of Income Tax for which matters are pending with the various appellate authorities:

SHIVA PHARMACHEM LIMITED					
Sr. No.	Name of Statute	Nature of Dues	Amount (In Rs. Lakhs)	Period to which amount relates	Forum where dispute is pending
1	Income Tax Act 1961	Income Tax	31.15	AY 2016-2017	ITAT Ahmedabad
2	Income Tax Act 1961	Income Tax	26.62	AY 2017-2018	ITAT Ahmedabad
TASH INVESTMENTS PRIVATE LIMITED					
Sr. No.	Name of Statute	Nature of Dues	Amount (In Rs. Lakhs)	Period to which amount relates	Forum where dispute is pending
1	Income Tax Act 1961	Penalty u/s 271(1)(c)	106.17	AY 2011-2012	CIT(A)-Vadodara
2	Income Tax Act 1961	Penalty u/s 271(1)(c)	172.94	AY 2012-2013	CIT(A)-Vadodara
3	Income Tax Act 1961	Income Tax	145.26	AY 2010-2011	ITAT Ahmedabad
4	Income Tax Act 1961	Income Tax	55.60	AY 2011-2012	ITAT Ahmedabad
5	Income Tax Act 1961	Income Tax	55.60	AY 2011-2012	Gujarat High Court
6	Income Tax Act 1961	Income Tax	NIL	AY 2012-2013	ITAT Ahmedabad
7	Income Tax Act 1961	Income Tax	NIL	AY 2012-2013	Gujarat High Court
8	Income Tax Act 1961	Income Tax	84.82	AY 2013-2014	ITAT Ahmedabad
9	Income Tax Act 1961	Income Tax	144.97	AY 2015-2016	ITAT Ahmedabad
10	Income Tax Act 1961	Income Tax	53.02	AY 2016-2017	CIT(A)-Faceless appeal
11	Income Tax Act 1961	Income Tax	22.42	AY 2017-2018	CIT(A)-Faceless appeal
12	Income Tax Act 1961	Income Tax	40.41	AY 2018-2019	CIT(A)-Faceless appeal
VR FINEHCHEM PRIVATE LIMITED					
1	Income Tax Act 1961	Income Tax	165.36	AY 2018-2019	CIT(A)-Faceless appeal



Shiva Pharmachem Limited
Additional information pursuant to Schedule III :

4. Trade Payables – MSME Vendor Outstanding & Interest on MSME Vendor:


Information required to be furnished as per Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) and Schedule III of the Companies Act, 2013 for the year ended March 31, 2022. This information has been determined to the extent such parties have been identified on the basis of information available with the Company:

Sl. No	Particulars	As on	
		March 31, 2022	March 31, 2021
1	<u>Principal amount due</u> to suppliers registered under the MSMED Act and remaining unpaid as at year end	756.92	999.74
2	<u>Interest due</u> to suppliers registered under the MSMED Act and remaining unpaid as at year end	1.28	1.87
3	<u>Principal amounts paid</u> to suppliers registered under the MSMED Act, beyond the appointed day during the year	---	---
4	<u>Interest paid</u> , other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	---	---
5	<u>Interest paid</u> , under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	---	---
6	<u>Interest due and payable</u> towards suppliers registered under MSMED Act, for payments already made	---	---
7	Further <u>interest remaining due and payable</u> for earlier years	---	---

5. Demerger of Shiva Performance Division:

Pursuant to implementation of Scheme 2, the unit of Shiva Pharmachem Limited located at Karakhadi (Performance Division), Vadodara was demerged w.e.f. October 1, 2019 and subsequently merged to Shiva Performance Materials Private Limited. The said arrangement was approved by the Ahmedabad bench of Hon'ble NCLT vide its order no. CP (CAA) No. 60/NCLT/AHM/2020 dated 18th December 2020. The approved arrangement was intimated by the Company to ROC on 01-02-2021 and accordingly became effective from 01-02-2021.

Under the said scheme, all the assets, liabilities, contracts, arrangements, employees, Permits, licenses, records, approvals, etc. relating to demerged unit of Shiva Pharmachem Limited have been transferred to Shiva Performance Materials Private Limited. The accounting treatment giving effect of the said arrangement has been given in the financials for the year ended 31st March 2021.



Shiva Pharmachem Limited
Additional information pursuant to Schedule III :

As per Clause 13 of the Scheme,

"All costs, Payments & Other Liabilities that the Demerged Company shall be required to bear to give effect to this clause 13 shall be borne solely by the Resulting Company and the Resulting Company shall reimburse and indemnify the Demerged Company against all liabilities and obligations incurred by the Demerged Company in respect thereof."

As a result of Demerger, the following joint liabilities as at 01/10/2019 have been demerged / separated as per Clause 13 of the Scheme to Shiva Performance Materials Pvt Ltd and reflected as Current Assets under the Balance Sheet of Shiva Pharma Chem Ltd.

Outstanding Balance As at 31.03.2022

Particulars	Amount (In Rs. Lakhs)
Shiva Performance Materials Pvt Ltd (LC-BG Limit)	747.22
Shiva Performance Materials Pvt Ltd (Working Capital Limit)	985.48
Total Rs.	1732.70

Moreover, clause 13 of the Scheme also provided as follows:

"It is clarified that till entry is made in the records of the appropriate authority(ies) and till such time as may be mutually agreed by the Demerged Company and the Resulting Company, the Demerged Company will continue to hold the property and / or asset license, permission approval, contract or agreement and rights and benefits arising there from as the case may be, in trust for and on behalf of the Resulting Company"


The joint operations continued till 31st May 2021 & wef 01st June 2021 demerged unit started its own functioning after receiving all statutory approvals. The amount outstanding as at 31st March 2021 & 31st March 2022 was actually a function of joint operations and the same have been apportioned as per approval of Hon'ble NCLT Order. Accordingly, they are not treated as loan transactions.

6. (a) Shiva Pharmachem Limited has entered into the Scheme of Arrangement in the nature of Amalgamation u/s. 230 to 232 of Companies Act 2013:

The Scheme of Arrangement of VR Finechem Private Limited into Shiva Pharmachem Limited has been approved by the Honourable NATIONAL COMPANY LAW TRIBUNAL, AHMEDABAD COURT NO. II vide its Order No. CP(CAA) 12/AHM/2022 IN CA(CAA) 70/230-232/AHM/2021 Dated - 26th September 2022. **The said Arrangement has been effective from 01st April 2021.** The Company has filed the order approved by the NCLT with Registrar of Companies, Ahmedabad (ROC) on 30-09-2022.

Under the said scheme, all the assets, liabilities, contracts, arrangements, employees, Permits, licenses, records, approvals, etc. relating to VR Finechem Private Limited have been transferred to Shiva Pharmachem Limited. The accounting treatment giving effect of the said arrangement has been given in the financials for the year.

The Scheme has accordingly been given effect in this financial statement with effect from 01st April 2021.




Shiva Pharmachem Limited
Additional information pursuant to Schedule III :

Pursuant to the effect of said scheme of arrangement, the following Assets, Liabilities & Reserves have been transferred to Shiva Pharmachem Limited as at 01/04/2021.

Particulars	Amount (in Rs. Lakhs)
List of Assets, Liabilities & Reserves transferred as at 01-04-2021	
<u>List of Assets</u>	
INVESTMENTS – Kis Chemicals Manufacturing & Mercantile Limited Liability Company	1660.92
DEPOSITS – RENT	0.36
HDFC BANK (IIFL)	0.02
IDBI BANK C/A	6.71
DEPOSITS - GOVT.	0.20
<u>Reserves & Surplus</u>	
RESERVE & SURPLUS - P&L BAL	(1032.91)
<u>Liabilities</u>	
UNSECURED LOAN – GIPL	1515.00
UNSECURED LOAN – SPL	414.00
INTEREST PAYABLE – GIPL	193.17
INTEREST PAYABLE – SPL	24.31
PROVISIONS FOR AUDIT FEES	0.80
CREDITORS	0.31
TDS PAYABLE - 94A @7.5%	3.50
TDS PAYABLE - 94J @7.5%	0.03

(b) As per IND AS 103 “Business Combinations” - The comparative financial information (FY 2020-2021) in the financial statement of Shiva Pharmachem Limited has been restated for the accounting impact of merger of VR Finechem Private Limited as if the merger had occurred from beginning of the comparative period i.e. from 01st April 2020.

(c) The Company Shiva Pharmachem Limited will issue 5,50,000, 8.5% Compulsorily convertible non-cumulative preference shares of Rs. 100 each as Purchase Consideration to the Shareholders of VR Finechem Private Limited pursuant to the scheme of arrangement become effective. This is in accordance with the Scheme of Arrangement approved by the honourable NCLT Ahmedabad Bench via Order Dated 26-09-2022.



Shiva Pharmachem Limited

Additional information pursuant to Schedule III :

7. Outbreak of COVID-19:

Due to outbreak of COVID-19 globally and in India, the Company's management has considered the impact of COVID-19 pandemic on its business operations and financial results based on its review of current indicators of future economic conditions and believes that the impact is likely to be short term in nature. The management does not see any medium to long term risks in the Company's ability to continue as a going concern and meeting its liabilities as and when they fall due.

However, the impact assessment of this pandemic is a continuing process given the uncertainties associated with its nature and duration. Despite reduced cases of COVID-19 being reported in the country, there have been massive disruptions in supply chain especially from global. Accordingly, the Company will continue to monitor any material changes to future economic conditions.

8. Loss due to Fire & Insurance Claim receivable:

A Fire took place on 30th October 2019 in the factory premises situated at Village Dahej, Vagra Dist. Bharuch, where Machineries of One plants and stock of semi-finished materials lying at said premises were completely destroyed. The total loss suffered by the company due to fire is estimated at Rs. 87.26 Lakhs. The company has lodged total insurance claims for such loss on account of fire for Rs. 87.26 Lakhs in October 2019. The insurers have not yet finalized the claims made by the company.

The difference if any, for claims receivables as provided in books by the company and actual receipt thereof the same shall be accounted for accordingly in the year of finality of the claim.

9. Title Deeds of Immovable Property not held in the Name of the company:

The title deeds of all the immovable properties, (other than immovable properties relating to Right of use assets where the Company is the lessee and the lease agreements are duly executed in favour of the Company) disclosed in the financial statements included in (Property, Plant and Equipment and capital work-in progress) are held in the name of the Company.

10. Working Capital/Borrowings:

The Company has been sanctioned working capital limits in excess of Rs. 5 crores, in aggregate, at points of time during the year, from banks or financial institutions on the basis of security of current assets. In our opinion and according to the information and explanations given to us, the quarterly returns and statements comprising (stock statements, book debt statements, and statements on ageing analysis of the debtors and other stipulated financial information) filed by the Company with such banks or financial institutions are in agreement with the books of account of the Company, of the respective quarters, except for the following:




Shiva Pharmachem Limited
Additional information pursuant to Schedule III :

For The Quarter	Sanction Amount to which the discrepancy relates (Rs. Crores)	Nature of Current Assets / Liabilities	Amount as per Quarterly Return & Statements (Amount in Lakhs)	As per Books of Accounts (Amount in Lakhs)	Difference (Amount in Lakhs)	Nature of Discrepancy	Remarks including subsequent rectification, if any
Mar-22	270	Inventory	10,186.62	10,174.95	11.67	Some obsolete inventories have been written off.	There is no revised statement filed till date
Mar-22	270	Trade Receivable	23,119.32	23,388.00	-268.68	Rs. 279.43 Lakhs M2M booked as at 31.03.2022 & Rs. 1.08 Lakhs due to TCS DN booked for the year 2022 at later date.	There is no revised statement filed till date
Jun-21	270	Creditors	4,773.55	4,790.88	-17.33	Invoice booking done at later date	There is no revised statement filed till date
Sep-21	270	Creditors	4,183.17	4,184.44	-1.28	Invoice booking done at later date	There is no revised statement filed till date
Dec-21	270	Creditors	3,605.21	3,641.33	-36.12	Invoice booking done at later date	There is no revised statement filed till date
Mar-22	270	Creditors	6,048.91	6,150.20	-101.28	Invoice booking done at later date	There is no revised statement filed till date

11. Other Statutory Information:

- (i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company does not have any transaction with struck off company.
- (iii) The company is not declared wilful defaulter by any bank or financial Institution or other lender at any time during the Financial Year.
- (iv) The Company has used the borrowings from Banks and Financial Institutions for the Purpose for which it was taken.



Shiva Pharmachem Limited

Additional information pursuant to Schedule III :

(v) The Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(vi) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(vii) The Company has not traded or invested in Crypto currency or Virtual Digital Currency during the financial year.

(viii) The Company has not advanced or loaned or invested funds to any other person(s) or entity, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(ix) The Company has not received any fund from any person or entity, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,

(x) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income-tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income-tax Act, 1961

For S S B K & Co
Chartered Accountants
(Firm Reg. No: 134956W)


CA Nitesh Thakkar


Partner

Membership No. 158383

Place: Vadodara

Date:

09 NOV 2022



For and On behalf of Shiva Pharmachem Ltd




Rakesh Agrawal

Chairman

DIN: 00057955

Place: Vadodara

Date: 09-11-2022



Vishal Agrawal

Managing Director

DIN: 00056800

Place: Vadodara

Date: 09-11-2022



Anil Inani

Chief Financial Officer

Place: Vadodara

Date: 09-11-2022



Tarang Maru

Company Secretary

Place: Vadodara

Date: 09-11-2022

SHIVA PHARMACHEM LIMITED
IND AS 101 DISCLOSURE

Effects of Ind AS adoption on Balance Sheet as at 1st April, 2020 and 31st March, 2021 and Comparative Information


Particulars	Explanatory Notes	As At 31st March, 2021		As At 1st April, 2020	
		Previous GAAP Values	Effects of transition to Ind AS	Previous GAAP Values	Effects of transition to Ind AS
(Last period presented under previous GAAP)					
			Ind AS Balance sheet		Ind AS Balance sheet
					Amount in Lakhs
					Amount in Lakhs
I ASSETS					
1. Non-Current Assets					
(a) Property, Plant And Equipment		16,155.32	-	9,606.00	9,606.00
(b) Capital Work - In - Progress		3,550.02	-	5,190.88	5,190.88
(c) Intangible Assets	(a), (c)	407.20	(400.00)	458.15	8.15
(d) Right To Use Asset	(b)	1,126.58	18.94	1,186.14	1,197.59
(e) Financial Assets					
(i) Investments	(e), (f)	2,440.52	(92.15)	2,444.02	2,351.87
(ii) Others Financial Assets	(g)	418.00	99.53	418.00	510.15
(f) Deferred Tax Assets (Net)	(f)	719.79	(594.59)	980.65	359.00
(g) Other Non Current Assets		255.47	-	240.05	240.05
Total Non-Current Assets		25,072.90	(988.27)	24,104.62	19,463.69
2. Current Assets					
(a) Inventories		7,401.25	-	6,345.08	6,345.08
(b) Financial Assets					
(i) Trade Receivables	(i)	14,266.54	(27.18)	17,964.47	17,964.47
(ii) Cash And Cash Equivalents		1,552.24	-	1,201.76	1,201.76
(iii) Bank Balances Other Than (ii) Above		216.97	-	430.74	430.74
(iv) Loans		446.01	-	36.89	36.89
(c) Other Current Assets		5,484.90	-	8,667.02	8,667.02
Total Current Assets		29,367.90	(27.18)	29,340.72	34,645.96
TOTAL ASSETS		54,440.80	(995.46)	53,445.34	54,109.65
II EQUITY AND LIABILITIES					
1. Equity					
(a) Equity Share Capital		708.02	-	695.02	695.02
(b) Instruments Entirely Equity In Nature*					
(c) Other Equity		30,230.45	(1,006.73)	23,377.95	22,306.29
Total Equity		30,938.47	(1,006.73)	24,072.97	23,001.31
2. Liabilities					
Non-Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings	(b)	3,519.20	-	5,646.97	5,646.97
(ia) Lease Liabilities		-	11.07	-	11.27
(b) Long Term Provisions		713.21	-	563.53	563.60
(c) Other Non Current Liabilities		139.70	-	34.87	34.87
Total Non-Current Liabilities		4,372.11	11.07	6,235.37	6,256.71



Current Liabilities						
(a) Financial Liabilities						
(i) Borrowings	9,858.23	-	9,858.23	16,633.05	-	16,633.05
(ia) Lease Liabilities	-	0.20	0.20	-	0.19	0.19
(ii) Trade Payables	-	-	-	-	-	-
(A) Total Outstanding Dues Of Micro Enterprises And Small Enterprises	998.74	-	998.74	595.99	-	595.99
(B) Total Outstanding Dues Of Creditors Other Than Micro Enterprises And Small Enterprises	4,701.10	-	4,701.10	3,976.68	-	3,976.68
(b) Short Term Provisions	1,605.96	-	1,605.96	906.91	(10.07)	896.84
(c) Liability For Current Tax (Net)	1,825.69	-	1,825.69	2,522.42	-	2,522.42
(d) Other Current Liabilities	139.49	-	139.49	226.46	-	226.46
Total Current Liabilities	19,130.22	0.20	19,130.42	24,861.52	(9.88)	24,851.63
TOTAL EQUITY AND LIABILITIES	54,440.80	(995.46)	53,445.34	55,169.85	(1,060.19)	54,109.65

Effect of Ind AS adoption on Profit and Loss for year ended 31st March, 2021

Particulars	Explanatory Notes	Previous GAAP Values	Effects of transition to Ind AS	Amount in Lakhs	
				Ind AS Balance sheet	
Revenue From Operations		52,773.63	-	52,773.63	
Other Income	(g)	1,529.74	7.37	1,537.11	
Total Income		54,303.37	7.37	54,310.74	
Expenses					
Cost Of Raw Materials And Components Consumed		28,332.00	-	28,332.00	
Purchase Of Traded Goods		-	-	-	
Decrease / (Increase) In Inventories Of Finished Goods, Work-In-Progress And Traded Goods		(1,296.92)	-	(1,296.92)	
Employee Benefits Expense	(k)	5,637.85	(91.29)	5,546.56	
Finance Costs	(b), (h)	534.94	0.92	535.86	
Depreciation And Amortization Expense	(a)	2,317.66	(57.49)	2,260.17	
Other Expenses	(b), (j)	9,490.60	26.08	9,516.68	
Total Expenses		45,016.13	(121.78)	44,894.35	
Profit Before Exceptional Items		9,287.23	129.15	9,416.39	
Exceptional Items		-	-	-	
Profit Before Tax		9,287.23	129.15	9,416.39	




Tax Expense					
Current Tax		2,300.00	-	-	2,300.00
Deferred Tax	(i)	260.86	4.84	-	265.70
Tax Credit Under Minimum Alternate Tax (MAT)	(i)	(139.13)	-	-	(139.13)
Excess/Short Provision: Income Tax		-	-	-	-
Income Tax Expense		2,421.73	4.84	-	2,426.57
Profit For The Year		6,865.50	124.32		6,989.82

Other Comprehensive Income					
Items That Will Not Be Reclassified To Profit And Loss In Subsequent Period					
Re-Measurement Losses On Defined Benefit Plans	(i)	-	(91.29)	-	(91.29)
Income Tax Effect		-	31.90	-	31.90
Net Gain/(Loss) On Fvtoci Equity Investments		-	-	-	-
Other Comprehensive Income For The Year		-	(59.39)		(59.39)
Total Comprehensive Income For The Year		6,865.50	64.93		6,930.43

Reconciliation of Total Equity:-


Nature Of Adjustments	Amount in Lakhs	
	As at April 01, 2020	As At 1st April, 2020
Equity As Per Previous Gaap	30,938.47	24,072.97
Finance Cost Of Lease Liability	(0.92)	-
Reduction In Amortization Of Rou Asset	7.49	-
Lease Rentals Now To Be Reduced From Lease Liability	1.10	-
Reduction Of Amortization On Goodwill Charged To P&L	100.00	50.00
De-Recognition Of Goodwill On Date Of Transition	(500.00)	(500.00)
Provision For Expected Credit Loss Allowances	(27.18)	-
Interest Component On PS	7.37	-
Deferred Tax Assets	(594.59)	(621.65)
Equity as per Ind AS	29,931.74	23,001.31



As per IND AS 103 "Business Combinations" - The comparative financial information of FY 2020-21 of Shiva Pharmachem Ltd has been restated for the accounting impact of merger with VR Finechem Pvt Ltd with comparatives as at 1st April, 2020. The details have been summarized below.

BALANCE SHEET AS AT 31ST MARCH, 2021

Particulars	As At 31st March, 2021			As At 1st April, 2020			Amount in Lakhs
	Ind AS Transited Values	Effects Of Merger	Ind AS Balance Sheet After Merger	Ind AS Transited Values	Effects Of Merger	Ind AS Balance Sheet After Merger	
I ASSETS							
1. Non-Current Assets							
(a) Property, Plant And Equipment	16,155.32	-	16,155.32	9,606.00	-	9,606.00	
(b) Capital Work - In - Progress	3,550.02	-	3,550.02	5,190.88	-	5,190.88	
(c) Intangible Assets	7.20	-	7.20	8.15	-	8.15	
(d) Right To Use Asset	1,145.53	-	1,145.53	1,197.59	-	1,197.59	
(e) Financial Assets	-	-	-	-	-	-	
(i) Investments	2,348.37	1,660.92	4,009.29	2,351.87	1,660.92	4,012.79	
(ii) Others Financial Assets	517.53	-	517.53	510.15	-	510.15	
(f) Deferred Tax Assets (Net)	125.20	-	125.20	359.00	-	359.00	
(g) Other Non Current Assets	255.47	0.56	256.03	240.05	0.56	240.61	
Total Non-Current Assets	24,104.62	1,661.48	25,766.10	19,463.69	1,661.48	21,125.17	
2. Current Assets							
(a) Inventories	7,401.25	-	7,401.25	6,345.06	-	6,345.06	
(b) Financial Assets							
(i) Trade Receivables	14,239.36	-	14,239.36	17,964.47	-	17,964.47	
(ii) Cash And Cash Equivalents	1,552.24	6.73	1,558.96	1,201.76	1.27	1,203.03	
(iii) Bank Balances Other Than (ii) Above	216.97	-	216.97	430.74	-	430.74	
(iv) Loans	446.01	(414.00)	32.01	36.89	-	36.89	
(c) Other Current Assets	5,484.90	(24.31)	5,460.59	8,667.02	-	8,667.02	
Total Current Assets	29,340.72	(431.58)	28,909.13	34,645.96	1.27	34,647.23	
TOTAL ASSETS	53,445.34	1,229.90	54,675.24	54,109.65	1,662.75	55,772.41	
II EQUITY AND LIABILITIES							
1. Equity							
(a) Equity Share Capital	708.02	-	708.02	695.02	-	695.02	
(b) Instruments Entirely Equity In Nature*	-	550.00	550.00	-	550.00	550.00	
(c) Other Equity	29,223.72	(1,032.91)	28,190.81	22,306.29	(817.36)	21,488.93	
Total Equity	29,931.74	(482.91)	29,448.83	23,001.31	(267.36)	22,733.95	
2. Liabilities							
Non-Current Liabilities							
(a) Financial Liabilities							
(i) Borrowings	3,519.20	1,515.00	5,034.20	5,646.97	1,866.27	7,513.24	
(ia) Lease Liabilities	11.07	-	11.07	11.27	-	11.27	
(b) Long Term Provisions	713.21	-	713.21	563.60	-	563.60	
(c) Other Non Current Liabilities	139.70	193.97	333.67	34.87	58.36	93.23	
Total Non- Current Liabilities	4,383.18	1,708.97	6,092.15	6,256.71	1,924.63	8,181.33	



Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings	9,858.23	-	9,858.23	-	16,633.05
(ia) Lease Liabilities	0.20	-	0.20	-	0.19
(ii) Trade Payables					
(A) Total Outstanding Dues Of Micro Enterprises And Small Enterprises	999.74	-	999.74	595.99	595.99
(B) Total Outstanding Dues Of Creditors Other Than Micro Enterprises And Small Enterprises	4,701.10	0.31	4,701.42	3,976.68	3,976.68
(b) Short Term Provisions	1,605.96	-	1,605.96	897.59	897.59
(c) Liability For Current Tax (Net)	1,825.69	-	1,825.69	2,522.42	2,522.42
(d) Other Current Liabilities	139.49	3.53	143.02	225.71	231.20
Total Current Liabilities	19,130.42	3.84	19,134.27	24,851.63	24,857.12
TOTAL EQUITY AND LIABILITIES	53,445.34	1,229.90	54,675.24	54,109.65	55,772.41

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH, 2021

Particulars	Amount in Lakhs			
	Ind AS Transited Values	Effects of Merger	Ind AS Balance sheet after Merger	
Revenue From Operations	52,773.63	-	52,773.63	
Other Income	1,537.11	-	1,537.11	
Total Income	54,310.74	-	54,310.74	
Expenses				
Cost Of Raw Materials And Components Consumed	28,332.00	-	28,332.00	
Purchase Of Traded Goods	-	-	-	
Decrease / (Increase) In Inventories Of Finished Goods, Work-In-Progress And Traded Goods	(1,296.92)	-	(1,296.92)	
Employee Benefits Expense	5,546.56	-	5,546.56	
Finance Costs	535.86	209.34	745.20	
Depreciation And Amortization Expense	2,260.17	-	2,260.17	
Other Expenses	9,516.68	6.21	9,522.89	
Total Expenses	44,894.35	215.55	45,109.90	
Profit Before Exceptional Items	9,416.39	(215.55)	9,200.83	
Exceptional Items	-	-	-	
Profit Before Tax	9,416.39	(215.55)	9,200.83	




Tax Expense				
Current Tax	2,300.00	-	-	2,300.00
Deferred Tax	265.70	-	-	265.70
Tax Credit Under Minimum Alternate Tax (MAT)	(139.13)	-	-	(139.13)
Excess/Short Provision: Income Tax	-	-	-	-
Income Tax Expense	2,426.57	-	-	2,426.57
Profit For The Year	6,989.82	(215.55)		6,774.27

Other Comprehensive Income				
Items That Will Not Be Reclassified To Profit And Loss In Subsequent Period				
Re-Measurement Losses On Defined Benefit Plans	(91.29)	-	-	(91.29)
Income Tax Effect	31.90	-	-	31.90
Net Gain/(Loss) On Fvtoci Equity Investments	-	-	-	-
Other Comprehensive Income For The Year	(59.39)	-	-	(59.39)

Total Comprehensive Income For The Year	6,930.43	(215.55)		6,714.87
--	-----------------	-----------------	--	-----------------

Reconciliation of Total Equity:-

Nature Of Adjustments	Amount in Lakhs	
	As At 31st March, 2021	As At 1st April, 2020
Equity As Per Restated Ind As Balance	29,931.74	23,001.31
Equity Shares Of VR Finechem Ceasing To Exist Pursuant To The Effect Of Merger	550.00	550.00
Retained Earnings Of VR Finechem Pvt Ltd Transferred To Shiva Pharmachem Ltd	(1,032.91)	(817.36)
Equity After Merger	29,448.83	22,733.95



Shiva Pharmachem Limited

Transition date (Opening) IND AS balance sheet of Shiva Pharmachem Limited as at 01st April, 2020

Note 1A First Time Adoption to Ind AS

The Company has adopted Indian Accounting Standards as notified by the Ministry of Corporate Affairs and has prepared the first Ind AS financial statements for the financial year ended 31st March 2022.

For periods up to and including the year ended 31st March 2021, the Company prepared its annual financial statements in accordance with accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP).

Ind AS 101 First Time adoption to Ind AS prescribes the accounting principles for first time adoption of Ind AS. It lays down various 'transition' requirements when a Company adopts Ind AS for the first time. The accounting under Ind AS should be applied retrospectively at the time of transition to Ind AS. However, Ind AS 101 grants limited exemptions from these requirements. The Mandatory and Optional exemptions opted by the Company are mentioned below.


Accordingly, the Company has prepared financial statements which comply with Ind AS applicable for the year ending on March 31, 2022, together with the comparative period data as at and for the year ended March 31, 2021, as described in the summary of significant accounting policies. This note explains the principal adjustments made by the Company in restating its Indian GAAP financial statements, including the balance sheet as at April 01, 2020, the Company's date of transition to Ind AS and financial statements as at and for the year ended March 31, 2020.

The accounting policies set out in note 01 have been applied in preparing the financial statements for the year ended 31 March 2022, the comparative information presented in these financial statements for the year ended 31 March 2021 and in the preparation of an opening Ind AS balance sheet at 1 April 2020 (the "transition date").

In preparing our opening Ind AS balance sheet, we have adjusted amounts reported in financial statements prepared in accordance with IGAAP. An explanation of how the transition from IGAAP to Ind AS has affected our financial performance, cash flows and financial position is set out in the following tables and the notes that accompany the tables. On transition, we did not revise estimates previously made under IGAAP except where required by Ind AS.

Given below are the mandatory exceptions and optional exemptions applied in transition from previous GAAP to Ind AS:

Ind AS 101 allows first-time adopters certain exemptions from the retrospective application of certain requirements under Ind AS. The Company has applied the following exemptions:



A. Mandatory Exceptions:

(a) Estimates:

As per Ind AS 101 an entity's estimates in accordance with Ind AS at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

Company's Ind AS estimates as at April 01 2020 are consistent with the estimates as at the same date made in conformity with the previous GAAP.

(b) Classification and Measurement of Financial assets and Financial Liabilities:

In accordance with Ind AS 101, the Company has assessed the classification and measurement of financial assets on the basis of facts and circumstances that exist at the date of transition to Ind AS.

B. Optional Exemptions:

(a) Property Plant and Equipment and Intangible assets:

In accordance of Para D7AA, the Company has opted to continue with the carrying amount of all its Property Plant and Equipment and Intangible assets measured in accordance with the previous GAAP as deemed cost on the date of transition to Ind AS.

(b) Leases:

The Company has recognised Lease Liability and Right of Use asset, as required by Ind AS 116, on date of transition to Ind AS. In accordance with Para D9B of Ind AS 101, the Company has recognised **lease liability** at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate at the date of transition to Ind AS and **right-of-use asset** at its carrying amount as if Ind AS 116 had been applied since the commencement date of the lease, but discounted using the lessee's incremental borrowing rate at the date of transition to Ind AS measure a right-of-use asset at the date of transition to Ind AS.

(c) Goodwill:


As the goodwill does not meet the definition of intangible asset as per Ind AS 38, the Company has opted to de-recognise goodwill as at 01st April 2020 as per para 10 of Ind AS 101.

(d) Investments in subsidiaries, associates and joint venture:

In accordance with Para D14 and D15 Ind AS 101, the Company has opted to continue with the carrying amount of its investments as deemed cost as at the date of transition to Ind AS.

(e) Classification of Equity Instruments:

In accordance with Para D19B of Ind AS 101, the Company has opted to classify its equity investments at Fair Value Through Other Comprehensive Income (FVTOCI) on the basis of facts and circumstances at the date of transition to Ind AS.



Explanatory notes to the transition from previous GAAP to Ind AS:

(a) Property Plant and Equipment and Intangible assets:

In accordance of Para D7AA, the Company has opted to continue with the carrying amount of all its Property Plant and Equipment and Intangible assets measured in accordance with the previous GAAP as deemed cost on the date of transition to Ind AS.

(b) Lease Liability and Right of Use Asset:

In accordance with Para D9B of Ind AS 101, the Company has recognised lease liability pertaining to SEZ Unit at Dahej, at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate at the date of transition to Ind AS and right-of-use asset at its carrying amount as if Ind AS 116 had been applied since the commencement date of the lease, but discounted using the lessee's incremental borrowing rate at the date of transition to Ind AS measure a right-of-use asset at the date of transition to Ind AS.

As on 31-03-2021 this has resulted in reduction of retained earnings on account of finance cost by Rs. 0.91 Lakhs as at March 31, 2021. The retained earnings have also increased by Rs 1.10 Lakhs on account of reversal of Lease rent on these Right of use assets and on account of reversal of depreciation amount by Rs. 7.84 Lakhs.

The Company has entered into Lease Agreement with M/s. Shruti Marine Services to take on lease ISO tanks for 12 Months (i.e. Rent Agreement will be renewed on Year on Year basis). Due to Lease Agreement validity for 12 Months falling under the criteria of "Short Term Lease" the ROU assets and liability not created as per IND AS 116.

Also, the Company has entered into Lease Agreement with M/s. Eurotainer to take on lease ISO tanks for 36 months but the Rent Agreement will be renewed on Year on Year basis. Due to Lease Agreement's validity for 12 Months falling under the criteria of "Short Term Lease" the ROU assets and liability not created as per IND AS 116.

(c) Goodwill:

As goodwill has been derecognised on date of transition the amount of Rs. 50 Lakhs amortization in statement of Profit and Loss has been added back to profit and Goodwill of Rs. 500 Lakhs has been derecognised resulting into reduction in Retained Earnings.

(d) Investment property:

As per Para 7 of Ind As 40 - "Investment Property", properties held to earn rentals or for capital appreciation or both is to be classified as investment property. However, as on date of transition to IND AS the Company does not have any Investment Property.

(e) Investments in subsidiaries, associates and joint venture:

In accordance with Para D14 and D15, the Company has opted to continue with the carrying amount of its investments as deemed cost as at the date of transition to Ind AS.

Further as per Ind AS 27 Separate financial statements When an entity prepares separate financial statements, it shall account for investments in subsidiaries, joint ventures and associates either:



- (a) at cost, or
- (b) in accordance with Ind AS 109

The Company has opted to account for investments in subsidiaries, joint ventures and associates at cost.

(f) Fair valuation of equity instruments:

Under Indian GAAP, the Company accounted for long term investments in quoted and unquoted equity shares as investment measured at cost less provision for other than temporary diminution in the value of investments. Under Ind AS, the Company has designated such investments as FVTOCI investments. Ind AS requires FVTOCI investments to be measured at fair value. At the date of transition to Ind AS, difference between the instruments fair value and Indian GAAP carrying amount (after adjusting the provision for diminution in value of investment) has been recognised as a separate component of equity, in the FVTOCI reserve, net of related deferred taxes.

As on the date of transition to IND AS, the Company has taken carrying amount of investment of M/s. Enviro infrastructure Co Limited as its Fair Value in absence of availability of Fair Value per share.

(g) Compound Financial Instruments:

Under the previous GAAP Investment in subsidiary in the nature of Preference shares is classified as investment under the head non-current investments and the same is valued as cost.

However, Ind AS 32 Financial Instruments presentation requires an entity to split a compound financial instrument at inception into separate liability and equity component. An entity recognises separately the components of a financial instrument that (a) creates a financial liability of the entity and (b) grants an option to the holder of the instrument to convert it into an equity instrument of the entity.

Ind AS 109 deals with the measurement of financial assets and financial liabilities. Equity instruments are instruments that evidence a residual interest in the assets of an entity after deducting all of its liabilities. Therefore, when the initial carrying amount of a compound financial instrument is allocated to its equity and liability components, the equity component is assigned the residual amount after deducting from the fair value of the instrument as a whole the amount separately determined for the liability component.

(h) Borrowings (Part of Financial Liabilities):

Under Indian GAAP, transaction costs incurred in connection with borrowings are amortised upfront and charged to profit or loss for the period. Under Ind AS, transaction costs are included in the initial recognition amount of financial liability and charged to profit or loss using the effective interest method.

As on the date of transition the Company have carried out the calculation of effective rate of interest in case of HDFC Term Loan. As there was no material difference arises between the ROI as per Sanction Letter (Market Rate) and calculated Effective Interest Rate, in such case, the Company has decided to continue the treatment & presentation as per original repayment schedule.



(i) **Deferred tax:**

Indian GAAP requires deferred tax accounting using the income statement approach, which focuses on differences between taxable profits and accounting profits for the period. Ind AS 12 "Income Taxes" requires entities to account for deferred taxes using the balance sheet approach, which focuses on temporary differences between the carrying amount of an asset or liability in the balance sheet and its tax base. In addition, the various transitional adjustments lead to temporary differences. According to the accounting policies, the Company has to account for such differences. Deferred tax adjustments are recognised in correlation to the underlying transaction either in retained earnings or a separate component of equity.

(j) **Expected credited loss allowances:**

Under Ind AS, expected life time credit provision is made on trade receivables. Under previous GAAP, the provision for doubtful debts was made using ageing analysis and an individual assessment of recoverability.

(k) **Re-measurement cost and Past Service cost of net defined liability:**

Both under Indian GAAP and Ind AS, the Company recognised costs related to its post-employment defined benefit plan on an actuarial basis.

Remeasurement Cost

Under Indian GAAP, the entire cost, including actuarial gains and losses, are charged to profit or loss. Under Ind AS, re-measurements comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets excluding amounts included in net interest on the net defined benefit liability are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI.

Past Service Cost

Under the Indian GAAP, past service cost is recognised as an expense on a straight line basis over average period until the benefits become vested. However, as per Ind AS past service cost are recognized immediately, following the introduction of, or changes to a defined plan regardless of whether the benefits thereunder are vested.

(l) **Other comprehensive income:**

Under Indian GAAP, the Company has not presented other comprehensive income (OCI) separately. Hence, it has reconciled Indian GAAP profit or loss to profit or loss as per Ind AS. Further, Indian GAAP profit or loss is reconciled to total comprehensive income as per Ind AS.

(m) **Statement of cash flows:**

The transition from Indian GAAP to Ind AS does not have material impact on the statement of cash flows, except for payment of lease liabilities, which were forming part of operating activity under Previous GAAP and are now included under financing activity.

